https://trial.medpath.com/news/397bd36e78333390/conditional-fda-approval-pathway-bill-introduced-in-house-insidehealthpolicy-com 2024-10-17T18:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/3117d6cec7925025/ab-science-faces-setback-in-ema-approval-for-als-treatment-webdisclosure 2024-10-17T18:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/daf11631a777b0e7/buprenorphine-naloxone-vs-methadone-for-the-treatment-of-opioid-use-disorder 2024-10-17T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/0a9d27aa4405c4a8/early-drug-treatment-in-preterm-patients-with-large-patent-ductus-arteriosus-at-28-weeks-or 2024-10-17T18:29:18+00:00 weekly 0.7 https://trial.medpath.com/news/f92672d8dd33e077/more-companies-share-upcoming-aao-presentation-information-modern-retina 2024-10-17T18:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/179b23c160031c3b/speakers-highlight-2024-regulatory-moves-in-hypertension-lipid-diabetes-therapies-healio 2024-10-17T17:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/f772bfc62655b036/clinical-study-on-conversion-therapy-of-hepatocellular-carcinoma-bmc-gastroenterology 2024-10-17T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/0ebb64279d3e9655/estimating-the-true-prevalence-of-mash-and-masld-in-the-us 2024-10-17T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/5dee6657d2dbdaba/breakthrough-in-treating-neurological-diseases-mirage-news 2024-10-17T16:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/a938ba03afb235dd/addition-of-thoracic-radiotherapy-to-first-line-treatment-of-egfr-mutated-metastatic-nsclc 2024-10-17T16:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/58071dc1534038fa/tafasitamab-plus-lenalidomide-wins-approval-in-mexico-for-asct-ineligible-r-r-dlbcl 2024-10-17T16:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/33977182509df3d9/custom-alterations-mending-genes-for-long-lasting-effects-newswise 2024-10-17T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/3cb0a6ab7fef5888/for-fred-hutch-biostatisticians-numbers-are-no-game-fred-hutchinson-cancer-center 2024-10-17T16:04:31+00:00 weekly 0.7 https://trial.medpath.com/news/249140e15f41d2a6/new-biomarker-predicts-immunotherapy-response-in-hepatocellular-carcinoma 2024-10-17T15:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/7a5c8aaf334b0ba7/four-people-died-after-receiving-the-russian-sputnik-v-vaccine-telegrafi 2024-10-17T15:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/60c82ee0cb2a82b2/yourgene-health-cystic-fibrosis-base-assay-receives-ivdr-accreditation 2024-10-17T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/371a8b30d5803638/can-avutometinib-win-the-title-of-first-breakthrough-treatment-for-recurrent-kras-rttnews 2024-10-17T14:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/0f28e4c70ebf0cfe/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-gelsolin-an-immune 2024-10-17T14:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/74d45fba34f3aa26/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing 2024-10-17T14:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/65456788ea5d2bb3/biostem-technologies-reports-breakthrough-results-in-a-diabetic-foot-ulcer-wound-biospace 2024-10-17T14:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/b722cab6d9853b4f/october-17-2024-ggc4h-pilot-finds-spanish-language-intervention-feasible-and 2024-10-17T14:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/bdfb266059942599/harmonized-data-quality-indicators-maintain-data-quality-in-long-term-clep 2024-10-17T14:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/0af961f3750298a9/cancer-focused-digital-health-startup-closes-after-an-fda-rejection-stat-news 2024-10-17T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/6c6429f553419271/fda-approves-foscarbidopa-foslevodopa-for-motor-fluctuations-in-adults-with-parkinson-disease 2024-10-17T13:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/6c6117591c7a802f/in-a-breakthrough-indian-scientists-develop-unique-method-to-treat-brain-tuberculosis 2024-10-17T13:53:40+00:00 weekly 0.7 https://trial.medpath.com/news/5c49c425fe88767e/long-term-t-cell-response-and-safety-of-a-tetravalent-dengue-vaccine-in-healthy-children 2024-10-17T13:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/465db7e0b9388d4a/avadel-pharmaceuticals-announces-fda-approval-of-lumryztm-sodium-oxybate 2024-10-17T13:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/fd659475a9cdd982/fda-extends-review-of-obeticholic-acid-ocaliva-snda-for-primary-biliary-cholangitis 2024-10-17T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/bf22437001fc3c37/bms-opdivo-bests-pfizer-s-adcetris-in-late-stage-hodgkin-s-lymphoma-study-biospace 2024-10-17T13:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/4e9a01096a7e6146/more-evidence-on-glp-1s-and-opioid-addiction-stat-news 2024-10-17T13:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/72b6a36d5612ca23/preparing-for-responsive-management-versus-preparing-for-renal-dialysis-in-multimorbid-trials 2024-10-17T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/0914c90cdf8521f5/alkeus-pharmaceuticals-announces-data-presentations-at-the-american-the-manila-times 2024-10-17T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/07e07e6b1e61e184/fda-can-approve-cheaper-copycat-of-heart-failure-drug-entresto-judge-says 2024-10-17T12:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/786861e2522066bc/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-quantisnow 2024-10-17T12:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/260942ff2ecd6ad7/zanubrutinib-shows-limited-cost-effectiveness-against-r-bendamustine-for-first-line-cll-treatment-in-china 2024-10-17T12:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/88e99db2111235cd/medidata-announces-rave-lite-to-support-growth-in-early-and-late-stage-clinical-trials 2024-10-17T12:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/1bf40036fc6049ab/igc-pharma-announces-patient-enrollment-at-toronto-s-baycrest-in-phase-2-trial 2024-10-17T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/5625983fbe6081d3/astrazeneca-receives-mhra-approval-for-wainzua-in-rare-nerve-disease-attrv-pn 2024-10-17T12:23:36+00:00 weekly 0.7 https://trial.medpath.com/news/75b993ce1d0c5062/diet-may-improve-brain-health-in-older-adults-with-obesity-national-institute-on-aging 2024-10-17T12:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/b3e99a31052cc232/more-than-100-women-with-advanced-cancer-have-already-participated-in-the-impact-cnio 2024-10-17T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/c8442301641edb52/teva-and-mabxience-add-additional-oncology-biosimilar-candidate-expanding-strategic 2024-10-17T11:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/8e920e45dc34e05e/melanoma-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-17T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/a94ea5e864482e28/minor-cannabinoid-shows-promise-in-reducing-anxiety-drug-discovery-news 2024-10-17T11:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/5274ed7fc2ca2668/marinus-pharmaceuticals-presents-clinical-data-from-pivotal-phase-3-raise-trial-in-morningstar 2024-10-17T11:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/fb95c7f9728b2ee7/rozanolixizumab-efficacious-in-older-patients-with-generalized-myasthenia-gravis-phase 2024-10-17T10:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/3fe3477bf97b0581/kind-announces-late-breaking-abstract-accepted-for-presentation-on-and017-clinical 2024-10-17T10:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/5d531e0402220797/dad-s-use-of-diabetes-med-metformin-won-t-raise-birth-defect-risk 2024-10-17T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/47ef20a036afe18b/concern-over-tga-rejection-of-alzheimer-s-drug-abc-listen 2024-10-17T09:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/a1a6db2d27d1e74b/for-multiple-sclerosis-medication-and-cognitive-behavioral-therapy-can-reduce-fatigue 2024-10-17T09:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/46efa17fa6b13d3d/australia-joins-eu-in-turning-down-alzheimer-s-drug-leqembi-pharmaphorum 2024-10-17T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/44e8439b28ab80de/latigo-biotherapeutics-doses-first-participant-in-phase-1-clinical-trial-of-ltg-305-for-non 2024-10-17T08:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/f26652db55d6f9a5/7th-annual-oct-dach-conference-to-address-clinical-trial-innovation-investment-and-diversity-challenges 2024-10-17T07:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/c89cd1778c30dd8d/comparative-analysis-of-single-versus-tandem-autologous-stem-cell-transplantation-in-nature 2024-10-17T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/65c23514bb64373f/acadia-pharmaceuticals-announces-health-canada-approval-of-daybuetm-trofinetide-for 2024-10-17T06:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/a0a3e4f09a32b4a2/radiopharm-ventures-to-produce-radioantibody-for-atomvie-bioprocess-international 2024-10-17T06:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/4cb19cbe7fdf08af/specialty-drug-coverage-disparities-create-access-barriers-as-pbms-push-for-benefit-integration 2024-10-17T05:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/3f394a7172922c39/investigational-antibiotic-shows-efficacy-safety-in-late-stage-trial-for-uncomplicated-gonorrhea 2024-10-17T05:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/d412e3ff30e711b4/first-in-human-hiv-vaccine-to-induce-virus-specific-neutralizing-antibodies 2024-10-17T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/573936098d7502eb/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-pharmacy-times 2024-10-17T04:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/fd87f8621fb736ca/a-randomized-clinical-trial-testing-digital-mindset-intervention-for-knee-osteoarthritis-pain-and 2024-10-17T02:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/9a6f88cdeb5dbaab/gene-editing-approach-helps-launch-first-in-human-clinical-trial-for-rare-genetic-disease 2024-10-17T01:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/13d5b723148307ad/ai-support-significantly-improves-her2-scoring-accuracy-in-breast-cancer-diagnosis 2024-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/855fe14a32457ad7/glaukos-reports-positive-phase-3-results-for-epioxa-ophthalmology-times 2024-10-16T23:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/b886d15712bce7dc/hivma-honors-outstanding-achievements-in-hiv-clinical-education-and-research-with-idsa 2024-10-16T23:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/5e1992092658219b/immunotherapy-boosts-survival-of-advanced-hodgkin-lymphoma-in-clinical-trial 2024-10-16T21:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/ae567c4b02cc912a/kidney-transplants-safe-when-donor-recipient-both-hiv-positive 2024-10-16T21:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/ccfabe7018768b86/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-stock-titan 2024-10-16T20:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/fd83b88be0308adf/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 2024-10-16T20:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/e6308739c4c03377/study-breast-cancer-drug-shows-potential-for-rare-appendix-cancer 2024-10-16T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/b9bdc062f2fb8002/j-j-trims-neuroscience-pipeline-seltorexant-in-alzheimer-s-disease-dropped 2024-10-16T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/073e1a59c5a48313/atlas-examines-tolerability-of-hedgehog-pathway-inhibitors-and-transition-to-io-in-mbcc 2024-10-16T19:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/5ab184cb9a745b2a/bionj-medidata-tackle-underrepresentation-in-clinical-trials-njbiz 2024-10-16T18:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/d7dc79c56da29519/fda-cleared-medical-devices-lack-proper-vetting-doctors-say-webmd 2024-10-16T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/40ad87e48857a3bb/rna-editing-stocks-soar-on-wave-life-s-breakthrough-trial-data-yahoo-finance 2024-10-16T17:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/70a7e8e58e67d810/eximia-research-network-expands-into-iowa-with-acquisition-of-integrated-clinical-trial 2024-10-16T16:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/8ea1f303b2b569a0/fda-puts-novavax-flu-vaccine-trials-on-hold-biopharma-dive 2024-10-16T16:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/a994ded60800bb55/addition-of-ramucirumab-to-osimertinib-in-tki-naive-egfr-mutant-metastatic-nsclc 2024-10-16T16:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/f9b446b6db58ef86/osimertinib-plus-savolitinib-generates-durable-responses-in-egfr-mutant-met-amplified-nsclc 2024-10-16T15:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/877867c6805557b8/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella 2024-10-16T15:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/57bbe79e3276259f/bridget-koontz-md-on-the-rationale-for-the-phase-2-nrg-gu011-trial-urology-times 2024-10-16T15:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/c16094faf91882de/synedgen-partners-with-barda-for-miist305-development-pharmaceutical-technology 2024-10-16T15:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/6a3d0232872bdcf5/wave-life-sciences-reveals-rna-editing-breakthrough-reports-first-ever-clinical-proof-of 2024-10-16T15:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/834bc72f986032be/bacterial-vaccine-shows-promise-as-cancer-immunotherapy-eurekalert 2024-10-16T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/3898813691209bfc/intellia-therapeutics-promising-outlook-with-ntla-2002-s-impressive-phase-ii-results-and 2024-10-16T15:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/2b7c8f8f2ec0399f/breakthrough-technology-leads-to-life-saving-treatment-for-deadly-skin-reaction 2024-10-16T15:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/1512089c32a713ef/opinion-addition-of-olanzapine-is-effectively-manages-nausea-during-t-dxd-treatment 2024-10-16T15:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/3f7576f53f048fa3/results-of-phase-i-trial-shed-positive-light-on-uni-494-for-acute-kidney-injury 2024-10-16T14:51:34+00:00 weekly 0.7 https://trial.medpath.com/news/225e3553ed3fe90d/obsidian-solutions-group-secures-direct-to-phase-ii-award-from-afwerx-to-enhance 2024-10-16T14:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/7f52c2be5678feb2/us-advisory-committees-pink-sheet-citeline 2024-10-16T14:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/b47373f9311a53d0/okyo-pharma-begins-phase-2-trial-for-ncp-treatment-investing-com 2024-10-16T14:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/1c0cdf70989f626d/buy-rating-for-alcon-based-on-potential-fda-approval-of-ar-15512-despite-mixed-phase-3-results 2024-10-16T14:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/b546d83ecb9c0ca7/clinical-trial-reporting-is-on-the-rise-nature 2024-10-16T14:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/cc84ee6e2f15aa80/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-markets-data 2024-10-16T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/fefdd76b8e5c85bc/first-patient-in-europe-dosed-in-the-clinical-phase-2b-pointer-study-placera 2024-10-16T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/712f8c2c21475ab4/a-controversial-approval-for-novocure-s-device-stat-news 2024-10-16T13:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/750e98bec2316fba/men-and-women-process-pain-differently-study-finds-uc-san-diego-today 2024-10-16T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/028464f0bc8e6b7a/jaguar-health-launches-fda-approved-oral-mucositis-prescription-product-gelclair-in-the-u-s 2024-10-16T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/4361daec0fd3fe81/mhra-expects-new-uk-clinical-trial-regulation-implementation-by-january-2026 2024-10-16T12:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/d8173c6e530991d3/european-commission-grants-orphan-medicinal-product-designation-for-navenibart-astria 2024-10-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/b47ea548d21fab05/theriva-biologics-announces-orphan-medicinal-product-globenewswire 2024-10-16T12:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/5f97ddd187a10a82/uconn-s-promising-stroke-medicine-one-step-closer-to-clinical-trial-testing 2024-10-16T11:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/f74de9c3b3a4314f/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global 2024-10-16T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/f19e240f9aba7afd/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude 2024-10-16T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/0c7eb8766f912750/fda-grants-breakthrough-device-designation-for-emerging-high-intensity-focused 2024-10-16T11:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/ad2da3ff6d1c93f6/cessatech-announces-that-recruitment-has-today-reached-the-halfway-point-for-patient 2024-10-16T11:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/ba1360e6c3f4e811/ai-tools-revolutionize-cancer-diagnosis-and-treatment-precision-expert-says 2024-10-16T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43f6e4cd5c0dd9b8/shilpa-medicare-s-us-customer-gets-fast-track-approval-for-glioblastoma-drug 2024-10-16T10:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/229c0e82b1fb29f1/merck-s-capvaxivetm-pneumococcal-21-valent-conjugate-vaccine-demonstrates 2024-10-16T10:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/c227b8d2fd8c1885/formycon-published-results-of-analytical-similarity-study-of-biosimilar-candidate-fyb206-and 2024-10-16T10:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/ec28507f7c84ab02/official-seal-of-approval-for-university-of-central-lancashire-s-clinical-trials-unit 2024-10-16T10:50:27+00:00 weekly 0.7 https://trial.medpath.com/news/6b165302bd07c912/what-journalists-should-know-before-diving-into-drug-investigations 2024-10-16T09:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/0648778aa82a4a8b/servier-steps-up-commitment-to-digital-innovation-for-patients-with-klineo-partnership 2024-10-16T09:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/48298148b4401713/efforts-to-increase-diversity-in-cancer-clinical-trials-fall-short-news-medical 2024-10-16T09:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/fefff01e958382b7/who-suspends-approval-process-for-russian-sputnik-v-vaccine-telegrafi 2024-10-16T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/9c6439b5bbc5d44e/uk-launches-2-clinical-trials-into-cannabis-and-childhood-epilepsy-but-serious-concerns 2024-10-16T09:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/a8dda3df7f2d6ac5/mayo-clinic-expert-removing-prior-authorization-for-biomarker-testing-could-improve-cancer-survival-rates 2024-10-16T08:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/484ce0fe17e3d991/canadian-medical-cannabis-outcomes-study-kicks-off-hemp-gazette 2024-10-16T08:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/df16bbb81a6237a5/wockhardt-gains-4-on-filing-for-dcgi-s-approval-for-its-insulin-injection-news-on-markets 2024-10-16T08:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/f98cf0bedf4bfd74/bioversys-announces-last-patient-last-visit-in-bv100-phase-2-clinical-trial-in-ventilator 2024-10-16T08:14:11+00:00 weekly 0.7 https://trial.medpath.com/news/ce9fe5e1f86adb50/bostongene-and-sarah-cannon-research-institute-collaborate-to-accelerate-the-biospace 2024-10-16T07:37:01+00:00 weekly 0.7 https://trial.medpath.com/news/609eb99fa9166294/avs-enrolls-first-patient-in-u-s-pivotal-intravascular-lithotripsy-study-biospace 2024-10-16T07:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/7ec55ca50f45306c/how-genes-determine-the-effectiveness-of-diets-in-irritable-bowel-syndrome 2024-10-16T07:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/0d1279c32126f3d6/language-barriers-in-clinical-research-trial-term-deters-patient-participation-study-finds 2024-10-16T06:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/67c05e8577cf8c18/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary 2024-10-16T06:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/07dca1de46fd9495/focus-on-long-term-protection-european-biotechnology-magazine 2024-10-16T06:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/619b8de2262caa5b/rising-costs-and-coverage-challenges-shape-anti-obesity-medication-landscape-in-us 2024-10-16T05:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/61201447b5d38136/hutchmed-announces-that-tagrisso-r-plus-orpathys-r-demonstrated-high-clinically 2024-10-16T05:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/7be4e0b8917e7408/stampede2-trial-explores-combination-niraparib-and-abiraterone-in-mhspc-urotoday 2024-10-16T05:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/ca00f3b782569d43/buy-rating-affirmed-for-novocure-as-fda-approval-expands-optune-s-market-potential 2024-10-16T04:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/39a51c0f7a3ab0fa/oncodesign-precision-medicine-s-a-inside-information-other-news-releases 2024-10-16T03:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/350984bcdc1a77c6/gsk-files-patent-lawsuit-against-moderna-over-mrna-vaccine-technology 2024-10-16T02:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/47216d103035eff2/hanmi-pharm-advances-6-new-drugs-into-clinical-trials-for-hypertension-diabetes-and-cancer-kbr 2024-10-16T02:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/eb07d9d1ab2cf949/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less 2024-10-16T02:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/53c38aa825b88c77/nyrada-gears-up-for-phase-i-clinical-trials-sharecafe 2024-10-16T00:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/e279fa516f1c5192/acelyrin-inc-forms-scientific-and-patient-advisory-board-biospace 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c23e543a21109dc3/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/73d911e7c4ffa247/safety-and-efficacy-of-the-blood-stage-malaria-vaccine-rh5 2024-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/36a9c188f2538753/dr-sallman-on-the-significance-of-the-fda-approval-of-luspatercept-for-lower-risk-mds 2024-10-15T22:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/b38a47c3dd4368ee/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-15T22:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/50fcfe93e44c4ac0/catalyst-orthoscience-announces-fda-510-k-clearance-for-shoulder-fracture-system-and 2024-10-15T21:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/f5c455d1f357d262/imforte-shows-benefits-of-lurbinectedin-atezolizumab-in-es-sclc-targeted-oncology 2024-10-15T21:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/ba7faa01710512fa/fda-approves-optune-lua-for-metastatic-nsclc-after-platinum-based-chemotherapy 2024-10-15T21:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/bf347ddecef8ca9f/meiragtx-looks-to-a-phase-iii-in-parkinson-s-bioworld 2024-10-15T21:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/81fae636da04d341/capmatinib-in-met-exon-14-mutated-nsclc-the-asco-post 2024-10-15T20:59:19+00:00 weekly 0.7 https://trial.medpath.com/news/2f6245c1308c0b96/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102-stock-titan 2024-10-15T20:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/5324a5c62f8fd560/uropot-study-protocol-for-a-randomized-double-blind-phase-i-ii-trial-for-metabolism-based 2024-10-15T20:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/4eba55bcb9542543/pharma-s-cold-calling-cgt-space-at-a-critical-crossroads-pharmaceutical-executive 2024-10-15T20:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/a2fb0c5fb1d0b018/eu-accelerated-assessment-tracker-insights-citeline 2024-10-15T19:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/3048f01f547789e2/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and 2024-10-15T19:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/8485641bc0bb5fac/study-resistance-to-antibody-rare-in-rsv-breakthrough-cases-cidrap 2024-10-15T19:19:36+00:00 weekly 0.7 https://trial.medpath.com/news/0d6603f12380ab33/ultomiris-over-half-year-helped-most-gmg-patients-in-phase-3-trial 2024-10-15T19:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/ae1424575f658de2/alzheimer-s-heparin-link-two-phases-of-alzheimer-s-damage-prion-disease-testing 2024-10-15T18:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/ec8aa5e110f389a5/experimental-drug-rk-33-shows-promise-in-treating-breast-cancer-bone-metastasis 2024-10-15T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/70003f7202b017ab/immune-profiles-forecast-immunotherapy-side-effects-drug-discovery-and-development 2024-10-15T17:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/3584f1a381a6618b/18f-rhpsma-7-3-pet-mri-demonstrates-high-detection-in-recurrent-prostate-cancer-urology-times 2024-10-15T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/b110a2f78a4c8835/why-are-we-still-seeing-gaps-in-women-s-heart-care 2024-10-15T17:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/39342a37a7327fb2/lyka-s-patent-pending-drug-pregabalin-gel-8-w-w-receives-approval-from-cdsco 2024-10-15T17:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/fc15fd07d0d25cd7/eye-on-pharma-aflibercept-legal-drama-pbm-humira-biosimilars-denosumab-regulatory-review 2024-10-15T17:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/2fd325eaa2c8fc28/allyx-therapeutics-awarded-3-3-million-nih-grant-to-globenewswire 2024-10-15T17:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/0efd1a0124573205/gsk-gets-fda-approval-for-meningococcal-vaccine-manila-standard 2024-10-15T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/66ed90b21f1e7796/lyra-therapeutics-fully-enrolls-pivotal-phase-3-enlighten-2-globenewswire 2024-10-15T15:54:53+00:00 weekly 0.7 https://trial.medpath.com/news/99f2c4552e785288/fda-clears-long-term-laser-treatment-for-inflammatory-acne-vulgaris-hcplive 2024-10-15T15:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/3c7555fab889fbb8/intermountain-medical-center-first-in-nation-to-use-fda-approved-device-to-treat-life 2024-10-15T15:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/be1c5cec5f828ef7/effects-of-a-mobile-health-intervention-based-on-a-multitheoretical-model-of-health-behavior 2024-10-15T15:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/6a2ca1ed1e4d750c/healix-study-aims-to-reduce-cervical-cancer-rates-and-health-disparities-uc-davis-health 2024-10-15T15:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/16627c1c29989b02/shining-new-light-on-breast-cancer-cells-mass-general-giving 2024-10-15T15:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/27c005f7fe2b6879/pfizer-invests-in-molecular-glue-jazz-meiragtx-shares-rise-on-drug-data-biopharma-dive 2024-10-15T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/29ec867d05fb1910/msk-research-highlights-october-15-2024-memorial-sloan-kettering-cancer-center 2024-10-15T15:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/599d4e67e098260f/uk-plans-weight-loss-drug-trials-to-get-people-back-to-work-dw 2024-10-15T15:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/a0a317b86709d3c2/clinical-trials-market-size-to-worth-usd-85-37-billion-by-2033-straits-research 2024-10-15T15:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/6f5a2d16ea2a572e/ventyx-biosciences-presents-new-52-week-results-from-the-phase-2-trial-of-vtx002 2024-10-15T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/7581948df547e593/pharmamar-announces-positive-and-statistically-significant-overall-survival-and-markets-data 2024-10-15T14:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/11ca5bb41f3d216a/first-in-human-open-label-dose-escalation-trial-with-expansion-cohorts-to-evaluate-the 2024-10-15T14:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/6073083f07fcd79b/predicting-response-to-rtms-in-mdd-psychiatric-times 2024-10-15T14:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/8fac5bc07e52d600/keynote-811-pembrolizumab-combination-in-first-line-setting-improves-overall-survival 2024-10-15T14:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/38ef92b9f1b192c5/laura-j-van-t-veer-phd-honored-with-2024-william-l-mcguire-memorial-lecture-award 2024-10-15T14:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/fed00f9a90180a47/chiglitazar-for-the-treatment-of-mash-phase-ii-clinical-study-selected-for-oral-presentation 2024-10-15T14:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/32b3b225449a9324/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-alzn-stock-news 2024-10-15T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/54b450498fd56a2c/trop2-offers-attractive-therapeutic-target-in-breast-cancer-and-other-solid-tumors-onclive 2024-10-15T14:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/b64765264b77b728/remote-monitoring-of-rheumatoid-arthritis-remora-study-protocol-for-a-stepped-wedge-trials 2024-10-15T13:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/0ce36fd7c4490e5f/government-to-spend-ps300m-on-weight-loss-drug-trials-the-times 2024-10-15T13:41:04+00:00 weekly 0.7 https://trial.medpath.com/news/740a1a0780fcc945/ocular-therapeutixtm-announces-accelerated-timelines-for-sol-1-registrational-trial-biospace 2024-10-15T13:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/4bc6e505d730653d/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in 2024-10-15T13:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/3cdb1d26afd471c5/lilly-s-omvoh-beats-j-j-s-stelara-in-head-to-head-phase-iii-crohn-s-disease-trial 2024-10-15T13:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/ced94bc2278afc08/immune-based-subgroups-uncover-diverse-tumor-immunogenicity-and-implications-for-frontiers 2024-10-15T13:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/83e1352d4d38539f/october-15-2024-case-study-describes-a-reassessment-of-sample-size-in-an-ongoing 2024-10-15T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/536875918eecc144/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-fast-track-yahoo-finance 2024-10-15T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/e629c8d411d75e30/uniqure-announces-dosing-of-first-patient-in-phase-i-ii-clinical-trial-of-amt-162-for-the 2024-10-15T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/6f68c77285fbdf4c/how-will-manchester-weight-loss-drug-trial-for-unemployed-work-bbc 2024-10-15T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/bb56abbc8b054d39/adaptive-research-launches-decentralized-clinical-trial-in-parkinson-s-disease 2024-10-15T12:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/d5d25ca2e7441961/immuneering-granted-orphan-drug-designation-for-imm-1-104-globenewswire 2024-10-15T12:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/6628ee4210abee2f/maia-biotechnology-announces-poster-presentation-of-novel-thio-prodrugs-at-ena-2024 2024-10-15T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/95a99fc29c6f0d21/vir-biotechnology-announces-clinical-advances-across-hepatitis-delta-and-hepatitis-b 2024-10-15T12:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/ef1fef4401fbeae6/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas 2024-10-15T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/c334ea566c4ec296/briacell-provides-phase-3-clinical-engagement-update-in-metastatic-breast-cancer-pivotal-study 2024-10-15T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/e5a00e3f7ae1c3e2/nivolumab-plus-anlotinib-hydrochloride-in-advanced-gastric-adenocarcinoma-and-nature 2024-10-15T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/984ddfc5179941c0/contego-medical-s-neuroguard-iep-system-receives-fda-approval-for-carotid-prweb 2024-10-15T12:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/98d25f2440171382/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-s-treatment-and 2024-10-15T11:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/5acb05390bbfc988/airway-therapeutics-to-launch-a-multinational-phase-3-trial-of-zelpultide-alfa-for-preterm 2024-10-15T11:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/57c47ea22a748aef/pheast-partners-with-lonza-to-produce-cancer-gobbling-cd24-drug-bioprocess-international 2024-10-15T10:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/e5f93b6ebf70ddc3/fda-grants-clearance-for-spectralis-flex-module-expanding-access-to-advanced-biospace 2024-10-15T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/930f4cd303ce01e2/wearable-tech-study-delivers-strong-results-for-cmt-clinical-trials-ein-presswire 2024-10-15T10:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/5c80d8128319d7fa/zeo-scientifix-a-leading-south-florida-biotechnology-company-launches-regenerative 2024-10-15T10:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/f1421a10bc1dd2d5/ananda-scientific-announces-a-clinical-trial-evaluating-nantheiatm-atl5-in-the-treatment 2024-10-15T10:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/e2be366fcad34b75/ema-drafts-concept-paper-for-future-radiopharmaceuticals-guideline-raps 2024-10-15T10:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/bc076b72396d4d45/bayer-applies-for-eu-approval-for-drug-to-treat-menopausal-symptoms-marketscreener 2024-10-15T09:38:55+00:00 weekly 0.7 https://trial.medpath.com/news/0fe9a23bb14652b4/oculis-diamond-phase-3-program-in-diabetic-macular-edema-globenewswire 2024-10-15T08:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/5313be923137b301/adolescent-drug-overdose-deaths-show-first-decline-since-pandemic-onset 2024-10-15T07:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/8e790a9b2e969a45/dr-voss-on-the-clinical-significance-of-the-keynote-564-study-in-ccrcc-onclive 2024-10-15T07:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/ce07ec20a91c420d/italy-italian-medicine-agency-new-guidelines-on-clinical-trials-global-compliance-news 2024-10-15T06:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/456573c9fb5b1d28/stratosphere-2-study-protocol-for-a-response-adaptive-randomised-placebo-controlled-trials 2024-10-15T06:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/5b50084aa6666aa8/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-stroke 2024-10-15T06:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/b568883e5c1efcf1/maat-pharma-completes-recruitment-of-its-ares-phase-3-trial-for-maat013-to-treat-acute 2024-10-15T05:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/d8dbe94d6bec0bc7/experts-discuss-treatment-strategies-for-advanced-rcc-focus-on-nivolumab-ipilimumab-combination 2024-10-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac3f4b1c879779ab/chest-2024-major-breakthroughs-in-copd-treatment-and-pulmonary-embolism-management-unveiled 2024-10-15T04:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/206ed10848a13c4c/forbion-secures-eur2-billion-in-landmark-biotech-investment-funds 2024-10-15T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/becc8c3d24a5d753/j-j-s-tremfya-and-carvykti-show-strong-growth-as-company-braces-for-stelara-biosimilar-competition 2024-10-15T04:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/db5df3c789214515/fda-grapples-with-ai-ml-medical-device-oversight-regulatory-gaps-and-bias-concerns-emerge 2024-10-15T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c7c50e093ae11f2/new-drugs-and-clinical-trials-amendment-rules-2024-mondaq 2024-10-15T02:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/28af028e9efdf1c4/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical 2024-10-15T02:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/6b7b828740d0a929/paratek-pharmaceuticals-announces-presentation-of-several-new-studies-of-nuzyra-biospace 2024-10-15T01:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/13c7e3def5cab2ba/plasma-proteomic-and-polygenic-profiling-improve-risk-stratification-and-personalized 2024-10-15T00:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/deb4ebe2f3c65f5d/tenecteplase-plus-thrombectomy-improves-stroke-outcomes-in-chinese-trial 2024-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fdb8a751a3704cb/taysha-seeks-to-overturn-natural-history-trends-with-rett-syndrome-gene-therapy-in-dual 2024-10-14T22:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/b2c27a4432822d3f/kod-kodiak-sciences-inc-latest-stock-news-market-updates 2024-10-14T21:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/32c9320538198064/dr-boreham-s-crucible-can-this-small-aussie-company-meet-mnd-s-sizeable-need 2024-10-14T19:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/f3f7c8e86f7033c0/the-role-of-established-pharmaceutical-companies-in-bringing-cell-therapy-to-cgtlive-r 2024-10-14T19:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/3486fac88443063a/selinexor-paves-the-way-for-more-affordable-effective-treatment-options-in-myelofibrosis 2024-10-14T19:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/2a1e6a773a3e7ad1/sotagliflozin-in-patients-with-type-1-diabetes-and-ckd-to-be-discussed-at-october-fda 2024-10-14T18:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/28ca8e68ee395a2a/electroconvulsive-therapy-for-the-treatment-of-dementia-symptoms-psychiatric-times 2024-10-14T18:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/35919199c5ca4db7/dr-john-byrd-87-and-dr-tom-goodwin-credited-with-early-work-on-cancer-drug-recently 2024-10-14T18:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/41fe6efcebe38ce5/fda-approves-ceftobiprole-medocaril-sodium-for-3-indications-drug-topics 2024-10-14T17:43:34+00:00 weekly 0.7 https://trial.medpath.com/news/fa6e36e0443bda67/the-u-s-fda-grants-fast-track-designation-to-coherent-biopharma-s-cbp-1008 2024-10-14T17:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/a1ac157c59d6e9ae/fda-facing-pressure-to-review-position-on-zepbound-mounjaro-shortage-biopharma-dive 2024-10-14T17:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/b2f1ba83766aaddf/abbott-teams-with-the-big-ten-conference-to-raise-blood-pharmaceutical-executive 2024-10-14T17:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/660e1d428bf4de29/recon-fda-may-rethink-shortage-listing-for-eli-lilly-s-tirzepatide-raps 2024-10-14T16:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/cb8f914f5e113815/glp-1-therapy-may-reduce-suicidal-ideation-risk-for-adolescents-with-obesity-healio 2024-10-14T15:54:35+00:00 weekly 0.7 https://trial.medpath.com/news/2aa1a338797388ab/collaboration-to-support-clinical-development-of-psma-targeting-theranostics-in-japan 2024-10-14T15:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/de230cffd3528084/anti-obesity-drugs-tied-to-lower-risk-of-suicidal-thoughts-or-attempts-among-young-people 2024-10-14T15:24:17+00:00 weekly 0.7 https://trial.medpath.com/news/7366ee00806db32a/icmr-and-zydus-lifesciences-initiate-second-phase-proof-of-concept-trial-for-desidustat-in 2024-10-14T15:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/6d5dc42b6bd40ef7/cf-may-have-stifled-her-before-but-now-she-can-laugh-sanford-health-news 2024-10-14T15:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/645dd8f43c4ccb48/the-october-2024-research-roundup-first10em 2024-10-14T14:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/d6e6ac6e686b7cf6/new-directions-in-all-cml-and-cll-treatment-the-asco-post 2024-10-14T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/fc9ebf40a2fed634/tpst-stock-touches-52-week-low-at-0-92-amid-market-challenges-investing-com 2024-10-14T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/81d6b58ec81cc02d/fianlimab-combo-shows-activity-in-advanced-melanoma-subtypes-cancer-network 2024-10-14T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/170f9fe1d4db0c52/aiims-bathinda-makes-breakthrough-in-stem-cell-therapy-research-for-heart-ailments 2024-10-14T14:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/e447340d5611afa0/biofrontera-inc-announces-database-lock-of-phase-3-study-of-ameluz-globenewswire 2024-10-14T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/b08d6392b6cebe35/mixed-active-metabolites-of-the-snp-6-series-of-novel-compounds-mitigate-metabolic 2024-10-14T14:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/011610aefbb09532/ischemic-stroke-drug-pipeline-research-report-2024-yahoo-finance 2024-10-14T14:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/f00e54ebbd69e094/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals 2024-10-14T14:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/5d4eb0ad6202c1e2/amgen-s-stock-falls-as-analyst-warns-that-hype-around-obesity-drug-is-baked-in-morningstar 2024-10-14T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/8384bcb9fccd2ee3/dr-tao-on-the-efficacy-of-avelumab-cetuximab-radiotherapy-in-cisplain-eligibile-vs 2024-10-14T14:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/fe5ae266c7731c65/chemoimmunotherapy-is-at-the-forefront-of-the-perioperative-nsclc-paradigm-onclive 2024-10-14T14:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/0384a64b019bb6e4/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal-significantly-enhancing 2024-10-14T13:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/a58e14cd377f457f/repare-therapeutics-doses-first-subject-in-phase-i-solid-tumour-trial 2024-10-14T13:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/6d4d98841b483274/lifevantage-introduces-the-mindbody-glp-1-systemtm-transforming-weight-management 2024-10-14T13:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/280b81192e1c042c/longeveron-r-lomecel-btm-data-in-alzheimer-s-disease-selected-for-late-breaking-poster 2024-10-14T13:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/46cd057910b08e17/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device-kilgore-news-herald 2024-10-14T13:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/7c19cad117f0ff24/exelixis-and-merck-collaborate-on-cancer-drug-trials-investing-com 2024-10-14T13:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/257927b16d47d343/relay-therapeutics-stock-holds-price-target-on-fda-approval-investing-com-uk 2024-10-14T13:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/a1e53124b736d3f0/early-phase-oncology-clinical-trials-unit-opened-at-mater-medical-independent 2024-10-14T13:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc4eb958939e082b/clinical-research-milestone-in-billings-means-hope-for-montana-residents 2024-10-14T13:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/723683f55715b861/clinical-trial-of-the-effects-of-postbiotic-supplementation-on-inflammation-oxidative-stress 2024-10-14T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/9a614f590c442377/nexalin-technology-appoints-carolyn-shelton-as-senior-vice-globenewswire 2024-10-14T12:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/d9be2109869a09f6/halia-therapeutics-to-participate-in-panel-at-bio-investor-forum-2024-kilgore-news-herald 2024-10-14T12:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/acc75ded839c55fb/comprehensive-biomarker-and-modeling-approach-to-support-dose-finding-for-bi-836880-a 2024-10-14T12:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/d61a17246e243947/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to 2024-10-14T12:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/9efde22603455fc7/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-14T12:26:07+00:00 weekly 0.7 https://trial.medpath.com/news/a64a17da953e611e/cepi-to-initiate-phase-ii-trials-of-a-rift-valley-fever-vaccine-in-kenya 2024-10-14T12:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/db424fe991ba758f/spyre-therapeutics-announces-expected-acceleration-of-spy003-il-23p19-markets-data 2024-10-14T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/2a497975b42e5b12/national-medical-products-administration-accepts-grand-pharmaceutical-group-limited-s 2024-10-14T12:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/05fc41c0b12a9f5b/meta-analysis-shows-efficacy-safety-of-car-t-cell-therapy-in-r-r-mantle-cell-lymphoma 2024-10-14T12:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/1f8842bdb400f973/global-protac-therapy-market-clinical-trials-drug-approval-insight 2024-10-14T12:07:38+00:00 weekly 0.7 https://trial.medpath.com/news/95d65ad58a8c43ef/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m11d1-in-relapsed 2024-10-14T12:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/0faafab3e9cdd318/phase-3-data-supports-the-long-term-safety-of-sts101-for-acute-treatment-of-migraine 2024-10-14T12:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/d46625b0548b45cb/lundbeck-makes-2-6b-cash-move-for-longboard-a-month-after-starting-phase-3-in-dravet-syndrome 2024-10-14T11:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/2bfb632f7fd808bc/non-viral-crispr-therapy-alleviates-symptoms-in-humanised-mouse-model-of-primary 2024-10-14T11:24:33+00:00 weekly 0.7 https://trial.medpath.com/news/9b515b9d437492e5/breakthrough-on-cervical-cancer-treatment-could-cut-deaths-by-40 2024-10-14T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/e1ad926de0af4cc7/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-stock-titan 2024-10-14T11:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/4a463611957e4269/bausch-lomb-receives-fda-approval-for-envista-r-envytm-full-range-of-vision-intraocular-lens 2024-10-14T11:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/e21c0ff12e9425e8/ozempic-plus-intestinal-zap-therapy-may-eliminate-need-for-insulin-in-type-2-diabetics 2024-10-14T10:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/714b14d900b2dbc8/mater-research-initiates-combined-covid-flu-vaccine-trial 2024-10-14T10:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/90ae3be4703a669e/experts-call-for-enhanced-provider-payer-collaboration-to-transform-value-based-oncology-care 2024-10-14T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/770425716b69a16b/bispecific-antibody-drug-conjugates-market-opportunity-globenewswire 2024-10-14T09:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/2f782a00d7e57c69/stgen-bio-secures-fda-cgmp-approval-for-songdo-bio-plant-komedidaskeom 2024-10-14T09:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/19b89abc8b7ca9ab/iteos-awaits-non-small-cell-lung-cancer-trial-data 2024-10-14T09:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/d4b0a878000f416e/bayer-applies-for-eu-approval-of-prostate-cancer-drug-for-another-indication 2024-10-14T09:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/fcbfdb3eaa25a356/transgene-share-price-falls-after-phase-ii-failure-marketscreener 2024-10-14T08:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/6aa45e212fe6fbec/gsk-reports-positive-results-from-depemokimab-trial-research-the-market-halifax 2024-10-14T07:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/87068154741e509f/turnstone-biologics-announces-strategic-restructuring-to-prioritize-portfolio-and-extend 2024-10-14T07:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/b7a589d13daef254/paradigm-shift-in-rare-cancer-research-biomarker-driven-approach-reshapes-oncology-landscape 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0214afa26e6c9707/medicare-faces-336m-waste-from-lecanemab-vial-sizes-in-alzheimer-s-treatment 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/611222d5ebf62ccf/inventiva-announces-filing-of-2024-half-year-report-conditions-for-accessing-or 2024-10-14T06:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/e7ceb3ffb9df688b/gsk-hails-phase-iii-nasal-polyps-success-proactive-investors 2024-10-14T06:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/e6288553d1384750/diamyd-medical-highlights-precision-medicine-approach-for-type-1-diabetes-at-the-cision-news 2024-10-14T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/622cfe9b04e8b708/inventiva-announces-financing-of-up-to-eur348-million-to-advance-the-nativ3-phase-3-mash-study 2024-10-14T06:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/c01ab61722458d58/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in 2024-10-14T06:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/ad50213c41e5be17/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic 2024-10-14T06:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/b01cd43b4fec806c/mayo-clinic-experts-address-cannabis-use-in-cancer-care-and-rising-drug-cost-challenges 2024-10-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5dfdf57b9b01704d/effectiveness-and-safety-of-azvudine-versus-nirmatrelvir-ritonavir-in-adult-patients-infected 2024-10-14T05:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/fa6dadec4e8d0d56/nicox-and-soleus-sign-16-5-million-royalty-and-equity-financing 2024-10-14T05:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/c410863dab029fad/data-driven-omnichannel-strategy-revolutionizes-healthcare-professional-engagement-in-pharma 2024-10-14T05:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/1b09aec4f24dfb24/ucb-receives-u-s-fda-approval-for-320-mg-single-injection-device-presentations-of 2024-10-14T05:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/dee6014437db0963/majority-of-children-with-spinal-muscular-atrophy-sma-globenewswire 2024-10-14T05:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/78577d9d4de052e4/breast-neurotization-a-breakthrough-technique-to-restore-post-mastectomy-sensation 2024-10-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2ed75214ee26d0f/cenyx-biotech-scores-nod-for-us-phase-1-trial-for-subarachnoid-hemorrhage-drug-kbr 2024-10-14T04:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/b6815be02b641bc6/ai-poised-to-transform-pharmaceutical-industry-with-208-billion-investment-by-2030 2024-10-14T04:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/5172420d7ecfa329/fda-action-alert-amgen-camurus-iterum-and-lexicon-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/aec5c7c094bb3fa0/5-accelerated-approvals-gone-wrong-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/2a6216781bc32a37/with-myriad-recent-approvals-in-cancer-the-era-of-bispecifics-is-here-biospace 2024-10-14T04:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/6ff9b4d4fd835a35/effect-of-endoscopic-ultrasound-guided-celiac-plexus-block-on-the-palliation-of-pain-in-trials 2024-10-14T03:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/8cc10d042c7ac6e7/imricor-eyes-worldwide-expansion-with-progress-on-us-and-eu-regulatory-approval 2024-10-14T03:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/7522960ceb8a9696/dual-drug-combo-potential-breakthrough-for-dementia-mirage-news 2024-10-14T03:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/2d1df890b0b77163/24-months-clinical-prospective-of-proximal-restorations-with-repeated-preheating-bulk-fill 2024-10-14T02:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/143149f095ccbff5/daewoong-pharmaceutical-s-diabetes-drug-wins-approval-in-ecuador-pulse 2024-10-14T02:29:36+00:00 weekly 0.7 https://trial.medpath.com/news/32dfed48b73c05a1/immuno-oncology-is-a-treatment-that-strengthens-the-immune-system-that-attacks-cancer-cells-it-effe 2024-10-14T02:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/2713d6c50110afe9/efficacy-analysis-of-haic-combined-with-lenvatinib-plus-pd1-inhibitor-vs-first-line-systemic 2024-10-14T01:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/000b0fc3aa36efba/privacy-friendly-evaluation-of-patient-data-with-secure-multiparty-computation-in-a-nature 2024-10-14T01:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/3e084312840fb6cf/shanghai-s-science-ecosystem-powers-pharma-giants-innovation-shine-news 2024-10-14T01:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/be299620313519db/guangzhou-baiyunshan-s-generic-drug-wins-approval-tipranks-com 2024-10-14T01:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/20274d25f16154bb/researchers-trial-stem-cells-to-cure-blindness-in-animals-bond-university 2024-10-14T01:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/aa4b1a7a32a1081c/digital-technologies-transform-cognitive-assessment-in-schizophrenia-drug-trials 2024-10-14T00:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/ca2c4249ffd46d83/ssy-group-s-muscle-relaxant-drug-secures-china-approval-tipranks-com 2024-10-14T00:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/14bfecfb08ae3d42/aptamer-drug-conjugates-loaded-bacteria-for-pancreatic-cancer-synergistic-therapy-nature 2024-10-14T00:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/6d1ab2196cb02fe7/ux111-for-sanfilippo-syndrome-type-a-mps-iiia-ultragenyx 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e3c223900143ea4f/pacritinib-response-is-associated-with-overall-survival-in 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3b3040214a65c643/clarity-pharma-shares-lift-on-clinical-trial-and-new-ceo-capital-brief 2024-10-13T23:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/185384c47599a1d9/effects-of-oxytocin-receptor-agonists-on-hair-growth-promotion-scientific-reports-nature 2024-10-13T23:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/c9d6ab46d27c98be/new-trials-into-benefits-of-cannabis-based-medicine-for-children-with-epilepsy-belfast-live 2024-10-13T23:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/5497573aafd45d47/children-with-aggressive-blood-cancer-offered-treatment-cure-hope-the-independent 2024-10-13T23:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/81878f63e6c0e11b/boy-has-300-seizures-a-day-until-he-takes-medical-cannabis-now-there-s-hope-for-others 2024-10-13T21:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/dad64a0112c2e2d0/ngs-technology-advances-promise-to-transform-precision-oncology-trial-recruitment-and-diversity 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7036ba60a088c907/clinical-outcome-assessments-a-critical-foundation-for-modern-drug-development-success 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/78282e82d8af1b1b/strategic-hub-partner-selection-critical-for-successful-drug-launch-and-patient-support 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05bfbd946174eb02/tvtx-investor-alert-bronstein-gewirtz-and-grossman-llc-globenewswire 2024-10-13T20:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/44d8dd4c77c022fe/blinklab-asx-bb1-is-this-exciting-company-the-next-resapp-stocks-down-under 2024-10-13T19:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/c5a6b151eaa0d924/her2-positive-treatment-resistant-breast-cancer-treatment-breakthrough-hmri 2024-10-13T17:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/ba4e1d5937e189a9/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy 2024-10-13T16:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/1534ad48efb269b0/cancer-breakthrough-new-miracle-treatment-yields-remarkable-results-this-could-be-the-cure 2024-10-13T16:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/f297ad89463e4790/startups-are-biohacking-psychedelic-drugs-to-make-sure-you-never-have-a-bad-trip-again 2024-10-13T16:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/0ac4489a68c97618/fda-gets-drugs-out-faster-but-some-work-only-marginally-better-and-are-more-expensive 2024-10-13T14:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/d597e7343581fd82/prostate-cancer-holy-grail-spit-test-could-save-nhs-ps500m-every-year-express-co-uk 2024-10-13T14:24:21+00:00 weekly 0.7 https://trial.medpath.com/news/adf7d72ddb30896e/internet-based-cognitive-behavioral-intervention-for-adolescents-with-anxiety-disorders-trials 2024-10-13T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/c78401a522ea16b7/point-of-care-hepatitis-c-test-may-expedite-diagnosis-contagion-live 2024-10-13T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/4010a069da97c529/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline 2024-10-13T13:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6efb6a95d6a07e0/gammora-breakthrough-hiv-treatment-to-be-presented-at-international-conferences 2024-10-13T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/27efb434a8ee114f/junshi-biosciences-ongericimab-wins-drug-approval-tipranks-com 2024-10-13T11:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/91f3f9258e828b4a/the-targeted-pulse-uncover-essential-developments-in-breast-cancer-multiple-myeloma 2024-10-13T11:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/fe69caaae3eb626b/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology-modern-retina 2024-10-13T10:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/63f86cf81afca67b/study-reveals-high-prevalence-of-fibromyalgia-in-post-covid-musculoskeletal-pain-patients 2024-10-13T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9420f6992f118124/sunvozertinib-granted-breakthrough-therapy-designation-by-china-cde-for-the-first-line 2024-10-13T08:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/245ae7ebe2127aff/ftc-takes-legal-action-against-top-pbms-over-insulin-pricing-practices 2024-10-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b6b3ad868524075/data-presented-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis 2024-10-13T04:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/7c66d1105b8a3b13/secukinumab-adalimumab-have-distinct-advantages-for-treating-psa-hcplive 2024-10-13T03:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/5597ffa5e9906c76/exact-sciences-launches-cologuard-plus-for-enhanced-colorectal-cancer-screening-in-adults-45-and-older 2024-10-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc83a50ff991e78c/new-regimen-could-improve-outcomes-in-transplantation-from-half-matched-donors 2024-10-13T01:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/7ca1b7d25860fa0e/breakthrough-that-means-most-lethal-cancer-is-a-death-sentence-no-more-how-miracle-drug 2024-10-13T01:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/9585297c687eb513/fda-approves-new-indication-for-navidea-s-lymphatic-mapping-agent-rttnews 2024-10-12T22:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/1b042462e604f21c/iv-secukinumab-rapidly-improved-clinical-responses-in-psoriatic-arthritis-hcplive 2024-10-12T21:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/deb7e554d1246cfd/u-s-fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug 2024-10-12T20:18:51+00:00 weekly 0.7 https://trial.medpath.com/news/01b9f1fb125b385a/scientific-advisory-committee-on-health-products-for-women-sac-hpw-canada-ca 2024-10-12T19:51:05+00:00 weekly 0.7 https://trial.medpath.com/news/f99a4931563f947f/2-biotech-stocks-that-are-screaming-buys-this-month 2024-10-12T17:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/ee2f6645794aa4be/race-based-correction-in-pulmonary-function-testing-in-copd-research 2024-10-12T17:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/345c973f51efc363/fda-says-medtronic-can-study-affera-pulsed-field-ablation-system-for-treating-ventricular-tachycardia 2024-10-12T17:40:31+00:00 weekly 0.7 https://trial.medpath.com/news/364d6710256cf00f/why-were-so-few-randomized-trials-of-public-health-and-social-measures-conducted-during 2024-10-12T16:33:21+00:00 weekly 0.7 https://trial.medpath.com/news/9018e29049296364/benitec-biopharma-reports-positive-data-from-two-subjects-globenewswire 2024-10-12T16:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/1679b582cb97b00c/7-year-old-paxton-in-remission-after-participating-in-new-cancer-drug-trial-at-ascension 2024-10-12T16:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/6b22b44fba2fbc83/breakthrough-new-pill-cuts-alcohol-consumption-by-over-50-the-brighter-side-of-news 2024-10-12T16:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/3aa0093ee625dc50/thyme-care-appoints-value-based-care-expert-dr-lalan-wilfong-to-lead-oncology-transformation 2024-10-12T14:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/8c4b3f9ef4f42377/thyme-care-secures-95m-series-c-funding-to-transform-value-based-cancer-care-delivery 2024-10-12T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9fac5f83c758bbd/neural-network-models-help-predict-immunotherapy-efficacy-in-small-cell-lung-cancer 2024-10-12T13:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/8397b1331fc6f881/corin-receives-fda-510-k-clearance-of-medial-constrained-tibial-insert-for-tka-healio 2024-10-12T13:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/7a60e6d719734ff9/remote-ischemic-post-conditioning-for-neonatal-encephalopathy-a-safety-and-feasibility-trial 2024-10-12T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/e606028edd9a87a3/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial 2024-10-12T13:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/851257cf7741239d/cgrp-monoclonal-antibodies-not-more-effective-than-topiramate-or-botox-for-treating-migraine 2024-10-12T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/ccd6d06bae63a2aa/study-identifies-genetic-factors-crucial-in-acute-myeloid-leukemia-survival-for-black-patients 2024-10-12T12:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/e0cb0f38eb5e07cc/fixed-duration-ibrutinib-venetoclax-elicits-meaningful-survival-benefit-in-high-risk-cll-sll 2024-10-12T11:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/83ce74f57fad82f9/home-blood-pressure-lowering-effect-of-esaxerenone-versus-trichlormethiazide-for-nature 2024-10-12T10:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/7d26be7ddbc87b63/market-today-cvs-exits-infusion-services-tesla-s-robot-controv-gurufocus 2024-10-12T10:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/01be6dfd41806b61/topiramate-pregabalin-reduce-headache-frequency-intensity-in-pediatric-migraine 2024-10-12T08:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/49a98e85b6163519/the-origins-of-modern-surgery-radical-mastectomy-and-the-first-randomized-trials-in-breast-cancer 2024-10-12T07:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/8899f94b955690a3/tirbanibulin-demonstrates-efficacy-for-actinic-keratosis-in-larger-field-treatment 2024-10-12T07:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/e212b678dd60ca92/hopa-president-highlights-evolution-and-challenges-for-women-in-pharmacy-leadership 2024-10-12T07:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce287a27378ab982/cisplatin-s-prevalence-in-bladder-cancer-falters-with-the-introduction-of-enfortumab-vedotin 2024-10-12T07:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/cec895876f39dca1/engineered-hsv-can-trigger-genetic-chain-reaction-rejigger-hsv-genes-during-co-infection 2024-10-12T04:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/d2910f94bb8b3abf/biomarker-testing-critical-for-optimizing-early-stage-nsclc-treatment-decisions 2024-10-12T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce5f17d651ff1135/sareum-holdings-completes-gbp2-4-million-fundraise-to-boost-lead-asset 2024-10-12T03:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/d064804ef0fea2b0/new-therapeutic-strategy-offers-hope-for-treating-aggressive-triple-negative-breast-cancer 2024-10-12T02:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/780a54dea82b7705/treatment-personalization-is-poised-to-define-new-era-of-mcrc-therapy-onclive 2024-10-12T02:22:46+00:00 weekly 0.7 https://trial.medpath.com/news/3ab74c3920cb3654/upstream-raises-255m-ipo-for-inflammatory-drugs-camp4-nets-75m-for-rna-work 2024-10-12T02:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/128a7ac30907fc5c/cancer-drug-could-be-used-to-save-the-limbs-of-peripheral-artery-disease-patients-pre 2024-10-12T01:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/28d06099e9bc210e/obesity-trial-surge-puts-the-focus-back-on-decentralisation-clinical-trials-arena 2024-10-12T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/4f7a839a1508dcfb/mace-in-cv-trials-has-the-outcome-outlived-its-role-tctmd-com 2024-10-11T22:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/da819e36020f1f89/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a 2024-10-11T22:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/7e097493e38bbe9d/lilly-extends-partnership-with-keybioscience-pharmaceutical-executive 2024-10-11T22:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/535486cb67b00921/dr-wolf-on-challenges-conducting-clinical-trials-evaluating-surgery-in-mesothelioma 2024-10-11T21:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/1424c5b431bdbe21/tezepelumab-for-severe-asthma-improves-the-odds-of-a-good-night-s-sleep-medpage-today 2024-10-11T21:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/137192d97325acce/innocan-pharma-s-lpt-cbd-shows-long-term-success-in-relieving-osteoarthritis-pain-in-dogs 2024-10-11T20:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/7bb8e97da7711916/bellaseno-s-clinical-trial-on-3d-printed-breast-implants-shows-promising-early-results 2024-10-11T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/71030f29c4827fe2/sanofi-discontinues-denali-partnered-ms-trial-after-phase-2-failure-endpoints-news 2024-10-11T20:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/d324cdb4523806c3/safety-data-favor-diuretic-strategy-triggered-by-cardiac-monitoring-alerts-in-hf 2024-10-11T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/b2ccfcb697af8ef2/this-week-at-fda-new-dscsa-exemptions-hemophilia-prophylactic-approved-and-more 2024-10-11T20:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/9d06061f9ecff2ce/fda-approves-single-dose-intravenous-paclitaxel-biosimilar-for-breast-cancer-onclive 2024-10-11T20:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/5f2eb146d3193eb8/pa-psychedelic-bulletin-176-drug-developers-discuss-trial-design-massachusetts-vote 2024-10-11T20:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/8f77c71e210ed9f4/norstella-introduces-a-fully-integrated-data-asset-for-biopharma 2024-10-11T19:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/89517d385dc4fff9/genentech-secures-fda-approval-for-inavolisib-in-advanced-hr-her2-breast-cancer 2024-10-11T19:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ff0df0d3810bc01/otc-markets-hosts-virtual-investor-presentation-with-christian-kanstrup-ceo-of-evaxion 2024-10-11T18:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/ceeaa73b71d1e0c1/fda-grants-orphan-drug-designation-to-lmp744-for-glioma-onclive 2024-10-11T18:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/c911112117256ccf/new-clinical-trials-begin-in-newcastle-for-pancreatic-cancer-patients-nbn-news 2024-10-11T18:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/2f0795df08697996/fda-sees-no-need-for-dccr-advisory-committee-meeting-prader-willi-syndrome-news 2024-10-11T18:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/1704c84f2d8e032e/uzedy-reducing-the-risk-of-relapse-in-patients-with-schizophrenia-psychiatric-times 2024-10-11T18:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/f795428cbc946bda/clinical-trial-finds-multidisciplinary-approach-improves-quality-of-life-for-movement-disorder-patients 2024-10-11T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/057786618401edc6/nccn-guidelines-for-mpn-reflect-new-drugs-focus-on-clinical-trials 2024-10-11T17:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/d0d5f775a375f321/pfizer-s-new-hemophilia-drug-hympavzi-gains-fda-approval-investing-com 2024-10-11T17:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/947b0e5e0073a273/acticor-biotech-repositions-glenzocimab-in-the-treatment-of-myocardial-infarction 2024-10-11T17:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/3fb3eee3f63be57d/u-s-food-and-drug-administration-approves-foundationone-r-liquid-cdx-as-a-companion 2024-10-11T16:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/e12db14ee6cf1d39/sublingual-epinephrine-film-moving-forward-nda-anticipated-by-early-next-year-healio 2024-10-11T16:22:36+00:00 weekly 0.7 https://trial.medpath.com/news/bbf91947ab0c8eb7/fda-accepts-elinzanetant-nda-for-menopause-symptoms-and-other-health-updates 2024-10-11T16:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/2d562ad00e875bcf/popliteal-plexus-block-compared-with-tibial-nerve-block-on-rehabilitation-goals-following-total 2024-10-11T16:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/9ca766da716d0f8b/fda-clears-roche-breast-cancer-drug-turnstone-lays-off-60-of-staff-biopharma-dive 2024-10-11T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/899536dc68c88e7a/glp-1-drugs-like-ozempic-may-protect-brain-health-several-studies-show 2024-10-11T16:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/919a078a9c8c030c/alzheimer-s-breakthrough-study-unveils-new-culprits-that-could-revolutionize-treatment-approaches 2024-10-11T15:56:11+00:00 weekly 0.7 https://trial.medpath.com/news/31c09676ceb7eca6/mirum-pharmaceuticals-volixibat-garners-buy-rating-amidst-breakthrough-therapy 2024-10-11T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/68dc49e195a23f65/eli-lilly-obesity-drug-on-track-for-japan-approval-next-year-ceo-nikkei-asia 2024-10-11T15:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/9a60fa584186bbb4/wockhardt-expects-pneumonia-drug-approval-in-india-soon-cnbc-tv18 2024-10-11T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/6211ac66ce1d49a9/an-antigen-discovery-pipeline-integrates-multi-omics-data-and-informs-immunotherapy 2024-10-11T15:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/8ea0dfdd32182121/hope-for-new-test-treatment-for-endometriosis 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/fb28871a92e507c7/wockhardt-gets-favourable-recommendation-from-cdsco-for-antibiotic-for-cabp 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/4328dd6c37a85922/disruption-of-asxl1-gene-improves-tumor-control-in-immunotherapy 2024-10-11T15:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/19ec4c4fd27dbafb/sintilimab-bevacizumab-in-relapsed-or-persistent-ovarian-clear-cell-carcinoma 2024-10-11T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/814a9056269fc1f6/tempest-therapeutics-shares-retain-buy-rating-post-roche-deal-investing-com 2024-10-11T14:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/1b8f1f0c7b37bc3e/admi-applauds-india-s-decision-to-maintain-stringent-clinical-trial-requirements-for-ivds 2024-10-11T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/b886fe2637a44062/graded-oral-challenge-safe-effective-for-pediatric-macrolide-allergy-hcplive 2024-10-11T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/abd295934bd19cde/aha-advocates-for-expanded-lipoprotein-apheresis-use-in-high-risk-cardiovascular-patients 2024-10-11T14:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/8856de413768a15d/viltepso-r-viltolarsen-injection-phase-ii-study-galactic53-trial-data-published-in 2024-10-11T13:56:21+00:00 weekly 0.7 https://trial.medpath.com/news/35e1000c7d73c0d2/sanofi-denali-abandon-mid-stage-multiple-sclerosis-study-on-disappointing-data 2024-10-11T13:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/05d6c184ef2b357a/acrivon-therapeutics-announces-initial-patient-dosing-in-globenewswire 2024-10-11T13:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/b4824d2fecee97e3/expert-outlines-key-factors-in-selecting-car-t-cell-therapies-for-follicular-lymphoma 2024-10-11T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9143e7f8c9a243dc/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and 2024-10-11T12:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/84ef40a2f9eac5a3/harm-effects-in-non-registered-versus-registered-randomized-controlled-trials-of-medications 2024-10-11T12:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/9c55539be8b3f0e5/patient-advocate-led-study-reveals-need-for-dosing-reform-in-metastatic-breast-cancer 2024-10-11T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/d5a4d43056bac3c0/cantargia-reports-new-positive-results-on-biomarkers-and-safety-in-can10-phase-1-clinical-study 2024-10-11T10:15:13+00:00 weekly 0.7 https://trial.medpath.com/news/cb10e9049c753b63/clario-partners-with-pathai-to-enhance-efficiency-in-gi-clinical-trials-yahoo 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/406cdd6a5d2e0d36/clinical-validation-of-a-tissue-agnostic-genome-wide-methylome-enrichment-molecular-pubmed 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/4551c1f4becde074/hivr4p-2024-research-highlights-reproductive-health-while-on-prep-and-signals-to-hiv-gov 2024-10-11T08:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/7b36e85aa240d812/lixisenatide-shows-promise-in-early-parkinson-s-disease-treatment-trial 2024-10-11T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8a80e8388e92d87/sclc-staging-determines-treatment-adverse-events-oncology-nursing-news 2024-10-11T07:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/a8af12784aa28ef9/clonal-evolution-study-reveals-treatment-patterns-in-lower-risk-mds-patients 2024-10-11T06:55:49+00:00 weekly 0.7 https://trial.medpath.com/news/4f5d5026f10fc33a/nih-names-3-hubs-for-primary-care-clinical-research-network-healthcare-innovation 2024-10-11T05:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/3afd4255a6873514/ruanjian-qingmai-granules-for-the-treatment-of-early-symptomatic-peri-ijgm 2024-10-11T05:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/5ed855fcbbab9cf6/experts-debate-optimal-sequencing-of-adcs-in-her2-low-metastatic-breast-cancer-treatment 2024-10-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c13458e94de273ff/nmpa-grants-marketing-approval-to-the-first-co-developed-ngs-based-companion 2024-10-11T04:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/915b5289db6d211b/eu-authority-mulls-paying-for-late-stage-research-as-a-pull-incentive-for-neglected-pink-sheet 2024-10-11T04:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/fd3c83935e6fb682/adaptive-deep-brain-stimulation-trial-results-poised-to-transform-parkinson-s-disease 2024-10-11T04:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/07be5519dde7a4fc/specialty-pharmacies-and-ambulatory-infusion-centers-drive-healthcare-cost-savings-and-enhanced-patient-experience 2024-10-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34ac1b3aaf3993f1/sanofi-enters-talks-with-cd-r-for-16-4b-consumer-health-unit-sale 2024-10-11T03:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/e306d1f574aa29af/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research-biospace 2024-10-11T03:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/e1a8aee299afe908/hussman-institute-alzheimer-s-experts-lead-apoe4-research-at-nih-meeting-inventum 2024-10-11T03:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/b6eca55bea7f9ac4/study-shows-new-drug-suppresses-systemic-inflammatory-response-syndrome-resulting-from 2024-10-11T02:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/83d93cf5ee976f8a/booster-therapeutics-launches-with-15m-to-develop-novel-proteasome-activator-platform-for-neurodegenerative-diseases 2024-10-11T02:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/978755baf08e8190/molecularly-targeted-therapeutics-are-precisely-aimed-onclive 2024-10-11T02:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/08996bd3377c7f20/vanqua-s-parkinson-s-drug-shows-promise-as-company-initiates-phase-ib-study 2024-10-11T01:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/ba3dc4dec3c11917/dong-a-st-s-stelara-biosimilar-imuldosa-scores-fda-approval-pharma-article-kbr 2024-10-11T01:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/355b8fba0657d9ab/cancer-drug-breakthrough-boosts-heart-patient-hopes-mirage-news 2024-10-10T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/fb1ca7c2c560f9d9/high-concentration-mabs-present-manufacturing-challenges-as-demand-surges-reports-cphi-europe 2024-10-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/17574a3f9e4cd029/bofa-securities-reiterates-buy-rating-on-alnylam-stock-highlights-amvuttra-launch-strategy 2024-10-10T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/5282e8b05f609ef8/let-s-talk-breast-density-cancer-movies-and-music-treatment-induced-aging 2024-10-10T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/761baaec705f5194/immatics-heads-to-phase-3-with-melanoma-cell-therapy-seeks-to-raise-150m 2024-10-10T21:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/d66836bff90f7567/an-interactive-game-for-people-suffering-from-nerve-pain-is-heading-to-clinical-trials 2024-10-10T21:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/ba761f56a18d4d58/immatics-off-to-phase-iii-with-ima203-after-positive-melanoma-results-scrip-citeline 2024-10-10T21:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/2a070d5c34d6272b/press-releases-thursday-oct-10-2024-genentech 2024-10-10T21:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/fe9be6ffa1db29f3/drug-rivals-face-off-in-pbc-after-fda-hands-down-2-new-approvals-1-advisory-snub-healio 2024-10-10T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/e4a728c3db491b08/drugmakers-are-racing-to-find-the-next-wegovy-these-obesity-trials-are-ones-to-watch 2024-10-10T20:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/9fe34e0a802582de/frontline-egfr-vegf-inhibition-slows-advanced-egfr-positive-lung-cancer 2024-10-10T19:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/332fb6adb804eda7/the-first-ever-antiviral-treatment-for-rsv-american-council-on-science-and-health 2024-10-10T19:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/a6cb7e45249eef8e/sotigalimab-may-be-a-safe-and-feasible-addition-to-the-rectal-cancer-chemoradiotherapy 2024-10-10T19:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/337e212c4c1998a0/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease 2024-10-10T19:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/2272e60488059f6c/clinical-trial-opportunity-for-afib-patients-who-don-t-take-an-anticoagulant-blood-clots 2024-10-10T18:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/f3a0d5040c1d34ca/cyrus-biotechnology-congratulates-david-baker-2024-nobel-laureate-in-chemistry-and 2024-10-10T18:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/0ef13416b32a9f21/hawai-i-cancer-consortium-expands-clinical-trial-access-to-address-healthcare-disparities-in-pacific-islands 2024-10-10T17:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/041f80d5bb321685/stronger-safety-considerations-needed-for-lumateprone-use-especially-for-women 2024-10-10T17:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/e35bd6fa1311768d/oxford-hospitals-research-unit-receives-ps1m-funding-bbc 2024-10-10T17:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/4bcc8732db0e360f/fda-grants-iota-biosciences-ide-approval-for-first-in-human-early-feasibility-study-with 2024-10-10T17:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/48e0c9e56cc17b35/bimekizumab-demonstrates-safety-and-efficacy-in-elderly-patients-with-psoriasis 2024-10-10T17:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/7d3009b64381d14c/sensorium-therapeutics-highlights-promising-data-on-lead-assets-targeting-anxiety 2024-10-10T16:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/ba49fb946b9d71f0/bayesian-approaches-in-drug-development-continuing-the-virtuous-cycle-nature 2024-10-10T16:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/dc885b3d677d13a6/happy-health-receives-fda-clearance-for-smart-ring-mobihealthnews 2024-10-10T15:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/a97f1b692d2b33ba/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-modern-retina 2024-10-10T15:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/467a838fd2a92f5b/q-a-first-of-its-kind-stent-for-neonates-very-young-with-pulmonary-stenosis-approved 2024-10-10T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/81ba705da0869b94/combination-therapy-may-improve-treatment-response-in-pancreatic-cancer 2024-10-10T14:52:26+00:00 weekly 0.7 https://trial.medpath.com/news/dfe1cd0590bbdd08/what-you-should-know-about-breakthrough-hiv-drug-futurity 2024-10-10T14:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/b4fd9aac848b9aa6/clinical-study-on-the-intervention-effect-of-digital-therapy-on-children-with-attention-deficit 2024-10-10T14:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/64af8ed6c2ffe9bc/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-stock-titan 2024-10-10T14:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/07ad8a92474c217a/antag-therapeutics-gets-fda-clearance-to-start-clinical-trials-with-new-obesity-drug 2024-10-10T14:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/1c4397176f566ce7/forget-epipens-this-san-diego-biotech-is-offering-the-same-medicine-without-needles 2024-10-10T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/ae16724c9ace115e/7-children-receiving-bluebird-s-gene-therapy-developed-blood-cancers-study 2024-10-10T14:17:10+00:00 weekly 0.7 https://trial.medpath.com/news/eea76f363a09820f/benmelstobart-plus-anlotinib-in-patients-with-egfr-positive-advanced-nsclc-after-failure-of 2024-10-10T14:16:35+00:00 weekly 0.7 https://trial.medpath.com/news/ec79fb6311101c02/grant-supports-gene-editing-research-for-rare-metabolic-diseases-news-medical 2024-10-10T14:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/b059c79e655da1b4/pfizer-phase-iii-prostate-cancer-win-builds-case-for-broader-label-for-talzenna-xtandi-combo 2024-10-10T14:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/7e2e17f453e7a124/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-biospace 2024-10-10T13:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/47c54e322a2c1133/comparative-analysis-of-durable-responses-on-immune-checkpoint-inhibitors-versus-other 2024-10-10T13:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/86a6ae41f96c2832/antibiotic-duo-effective-against-drug-resistant-infections-study-kff-health-news 2024-10-10T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/9ff34190c74328e3/highly-targeted-approach-supports-als-gene-therapy-development-als-news-today 2024-10-10T13:27:38+00:00 weekly 0.7 https://trial.medpath.com/news/b5a9fbb609da0d62/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to 2024-10-10T13:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/74abd8b97b2a0727/tailored-approaches-to-tki-dosing-allow-for-treatment-free-remissions-and-reduced 2024-10-10T13:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/ff8ed1efab4d0936/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100-tipranks 2024-10-10T13:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/895fa899900a3358/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-pbc 2024-10-10T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/d2af5da6afd8c997/achieve-life-sciences-announces-completion-of-enrollment-in-orca-ol-clinical-trial-biospace 2024-10-10T13:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/6c5f8d9e5cdd0d32/movano-health-provides-update-on-fda-review-of-eviemed-ring-move-stock-news 2024-10-10T12:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/bb78ac8292e01bed/international-myeloma-foundation-launches-clinical-trial-globenewswire 2024-10-10T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/fd0db87fe12a0531/attain-phase-iii-study-of-etirinotecan-pegol-versus-treatment-of-physician-s-choice-in 2024-10-10T12:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/777623315338daea/ai-simulations-help-drug-trials-forbes 2024-10-10T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/50faa2466754bbc4/melt-pharmaceuticals-announces-dosing-of-last-patient-in-pivotal-phase-3-study-of-its-lead 2024-10-10T12:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/5fa97f32ebeb9193/a-multicentric-randomized-controlled-clinical-trial-to-study-the-impact-of-bedside-model 2024-10-10T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/bda9a29df2204ecb/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-r-vs-stock-titan 2024-10-10T12:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/56862b86c2245908/micrornas-won-the-nobel-will-they-ever-be-useful-as-medicines-nature 2024-10-10T12:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/647042fb176151f4/a-randomized-phase-ii-study-of-veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus 2024-10-10T11:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/043dc6c2c2944197/priovant-mulls-broad-autoimmune-indications-for-brepacitinib-clinical-trials-arena 2024-10-10T11:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/9d9a86a1f981c44d/tempest-therapeutics-partners-with-roche-on-cancer-trial-investing-com 2024-10-10T11:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/6b4dfcec91641f6f/ananda-announced-phase-1-clinical-trial-in-australia-hellenic-suffers-further-funding 2024-10-10T11:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/200ffe1a3b6c4251/pharming-group-announces-start-of-phase-ii-clinical-trial-globenewswire 2024-10-10T11:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/1d241aab3eee0fda/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on 2024-10-10T10:48:17+00:00 weekly 0.7 https://trial.medpath.com/news/9d0005a0514f1dba/breakthrough-study-identifies-new-targets-for-combating-drug-resistant-cancer-the-statesman 2024-10-10T10:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/0f81aa77f3f1be1e/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/5541bd2b762b8fd6/could-lingering-infection-be-causing-long-covid 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/f118279b117ed5d5/new-life-changing-myeloma-drug-approved-for-fourth-line-use-on-the-nhs-for-those 2024-10-10T10:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/3d576b26de05fc11/bridget-koontz-md-18f-flotufolastat-demonstrates-high-detection-rate-in-low-psa-setting 2024-10-10T10:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/7e62be0f7fc2cc0a/experts-emphasize-early-detection-and-personalized-treatment-advances-during-breast-cancer-awareness-month 2024-10-10T10:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/00efaeb675ac0613/diamedica-gets-sahpra-approval-for-phase-ii-preeclampsia-treatment-trial-yahoo-finance 2024-10-10T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/news/faff1736e4ab405f/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-10-10T09:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/b209418529a7a569/low-cost-blood-drug-saves-thousands-of-trauma-patients-lives-nihr 2024-10-10T08:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/8b620e26283d85c9/study-uncovers-mechanism-of-mx-protein-in-fighting-hiv-1-and-herpes-simplex-virus 2024-10-10T08:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/a81ef51928472028/alzecure-pharma-broadcasts-live-event-about-the-phase-ii-candidate-acd440-against 2024-10-10T08:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/40e415eb7ac3dd5f/ab-science-revenues-for-the-first-half-of-2024-and-update-globenewswire 2024-10-10T06:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/ecf51b905648bd14/harbour-biomed-announces-publication-of-the-phase-i-study-results-for-porustobart-morningstar 2024-10-10T06:36:21+00:00 weekly 0.7 https://trial.medpath.com/news/09b822f95cfbb959/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa 2024-10-10T06:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/452985b8c95f7394/cantargia-s-phase-ii-results-published-in-clinical-cancer-research-marketscreener 2024-10-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/f40013494c35abbf/fda-s-final-rule-on-laboratory-tests-reshapes-medical-start-up-landscape 2024-10-10T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/297a7bb3d9ad14a2/ai-models-show-promise-in-pulmonary-embolism-diagnosis-doximitygpt-achieves-70-accuracy 2024-10-10T05:14:34+00:00 weekly 0.7 https://trial.medpath.com/news/ed97b80823f2f564/protein-prediction-wins-chemistry-nobel-alnylam-submits-an-all-important-drug-application 2024-10-10T04:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/06620b38e57cbe62/johnson-johnson-completes-v-wave-acquisition-cardiovascular-business 2024-10-10T03:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/8b156763416d2824/gummy-drug-delivery-systems-show-promise-for-patient-compliance-face-manufacturing-challenges 2024-10-10T03:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/ef5cd566e142e96b/activist-investor-starboard-claims-former-pfizer-executives-faced-threats-over-support-for-company-reform 2024-10-10T03:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/bfa748fe91f8dbd0/namodenoson-earns-fda-orphan-drug-designation-in-pancreatic-cancer 2024-10-10T03:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/93d2a37a255f43a2/arda-therapeutics-raises-43m-series-a-to-advance-novel-cell-depletion-platform-for-chronic-diseases 2024-10-10T02:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/4a6bf82ba05c55b9/eversana-s-direct-to-patient-model-revolutionizes-healthcare-access-through-digital-innovation 2024-10-10T01:23:38+00:00 weekly 0.7 https://trial.medpath.com/news/b0111ddb454ffc86/purplelab-to-host-webinar-on-data-driven-physician-prescribing-analysis-and-kol-engagement 2024-10-10T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/94add740c943a895/how-tecelra-r-approval-is-transforming-tcr-t-cell-therapy-news-medical 2024-10-10T00:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/bac5c67e15857a92/nih-launches-large-study-to-tackle-type-2-diabetes-in-young-people 2024-10-10T00:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/4c5eb438f5cd6dfc/intra-arterial-pressure-enabled-drug-delivery-enhances-liver-tumor-treatment 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/39104f96d0ec824c/dusseldorf-upc-ruling-clarifies-imminent-infringement-standards-for-biosimilars 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf0ae002f25fd498/emis-wins-innovation-award-for-revolutionary-clinical-trial-recruitment-platform 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd03bdc164ac25dd/digital-clinical-trials-show-promise-in-reducing-costs-despite-implementation-challenges 2024-10-09T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f9b0707380c8063/i-20-rehabilitation-project-entering-phase-3-shreveport-ksla 2024-10-09T22:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/385647c74eb5abfc/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy-clinical-trials-arena 2024-10-09T22:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/9517406774b711f9/kalivir-doses-first-subject-in-phase-i-ib-solid-tumour-treatment-trial 2024-10-09T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/213a3268e7e2d8c9/nurse-led-pilot-aims-to-improve-patient-access-to-clinical-trials-nursing-times 2024-10-09T21:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/fac3d04f58fa5053/4sc-ag-fra-vsc-q2-2024-earnings-call-highlights-strategic-advances-amid-financial 2024-10-09T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/cc4187ecc387f9cd/medtronic-launches-avalus-ultra-valve-in-western-europe-at-eacts-congress 2024-10-09T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/2fa14ca710967deb/clearside-clears-way-for-phase-iii-after-positive-cls-ax-results-in-wet-amd-scrip 2024-10-09T21:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/bd39950e57f9fe80/moleculin-biotech-inc-reports-promising-results-for-annamycin-in-aml-treatment 2024-10-09T21:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/5ed8e3a4291e0227/ai-biotech-insitro-partners-with-lilly-on-metabolic-disease-drugs-endpoints-news 2024-10-09T20:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/72aab03ec71c3f3c/a-walk-in-her-flip-flops-el-centro-mayor-shares-story-of-kidney-cancer 2024-10-09T20:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/8e7cb3526adc28de/liu-s-insights-on-navigating-the-fragility-of-phase-3-trials-targeted-oncology 2024-10-09T19:03:17+00:00 weekly 0.7 https://trial.medpath.com/news/cedfa353198e1656/complex-randomization-delivered-successfully-clinical-leader 2024-10-09T18:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/e0d7d109e61ab67a/neoadjuvant-sunitinib-plus-exemestane-in-post-menopausal-women-with-hormone-receptor 2024-10-09T18:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/a43e6d2b1186a45a/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/8eda98aa8a3eac7a/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/news/260298d023f9b65b/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/486637c006398780/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/26d29190e5d0333c/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/a7f857d36640b6ad/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/956e5e30f1869b49/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/b9c01473132d28df/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/3c3d8e28d68ea8ab/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/news/a58aa7d7fa92ff1d/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/2489cb2dba4493c3/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/49851acb640742d4/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/8f291316745de150/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/9dcd4c7d099a3e99/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/abd1b620c4526490/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/a61bb0d684b41ea1/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/c02300bbb0cfb8a8/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/fe865dbd2432f2d0/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/6b5709aad80b11fa/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/3cab4a8d7bb0a68a/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/news/131316809fa91c5b/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/d3bf5350760764bf/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/59c26bc17d869ec8/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/5a70cd42c247787e/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/3b4458077edf8368/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/dcf296ae32e3899a/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/acb9fbb94884944d/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/a1544947100509e9/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/af4caeeaa4c71042/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/77f929d10fd95d05/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/c89f9f84f33d4f27/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/a9b03bce799ba476/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/160a88e65b6a2c2e/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/58e41d45a4c0e9d2/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/3883db56051f81e7/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ed108ea5456b0656/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/24d16048563879e5/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/3f308392230d32fd/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/70222dd6675492e6/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/c79576a772ef25b8/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/c13ecc97ed36155d/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/37e7a4873b16ff80/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/6ecc0e5d6154e613/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/ee15286929a68116/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/94a43543f1e06812/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/cb14b02e45a37bad/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/eca2fae044ced88b/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/news/f18d426481d218b3/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/b401577a80336518/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/cde76f2fd912174e/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/cb4f47c8449561e0/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/4d9a4a27900410ec/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/2f172160b456e49c/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/5852c58336ac475a/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/98cc86f1b9dc8602/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/664ae8ffb3b9d0b9/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/fad0f34feca55105/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5714c97542e4029c/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/0ee14a8edf06d19c/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3612df547875939/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/b84590c4b4e6a20a/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/de03c867d5761e79/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/27e445b19805e5ba/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/b7e92508bcdcf12c/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/71f546007e0210df/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/d2e8d1e9b939c6d4/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/589c7e98eec3307a/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/480dc4c5505ace79/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/6b734c0788c1850e/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9788d1ae4402be95/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/5a16a79a4363e000/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/a97a112273a686d3/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b81c66cf3bd6e85/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/084d39b49014ea95/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/7cf1011f3c3b8fc9/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/516e4a98ffdbbce2/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/3ac61172493eee76/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/82440d3fbebcda2d/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/ac7b9bdee54c36d9/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/a2b8f430923cd150/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/225959852568d60c/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/8593a151397fcbbe/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/6a32a315abda5c05/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/d3a7fca53ccede53/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/1c8ed78b26627aa2/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/82bc95e1034ecc68/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/db2aa836f62f9938/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/4aa432670fa14532/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/34858970d36828d3/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/31c9ff3244c271d6/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/b898aa12ef6c1735/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/918b314af97e3f58/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/news/3c77cf99126cd577/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/93100fc7483560e6/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/63fcf6b356811958/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/98ff9a7393f74bd5/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/dcd6e94d48ea23f6/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/14c2f64290a1664b/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/5c3d197ba2aea3d3/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/0bbbdfa8c163e9bf/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/dde61ec85c4f4285/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/f45e3b6a59b33f55/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/news/663e1fbd1e80f339/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/1bb73bfa2f98f3dc/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/3ea20353bb7dfc7e/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/0680932f80f1ac82/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/f5d95cb19a2588cf/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/68d6a0c0e9fcec61/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/2fcc968f5abcaa93/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/d5573ae697269b30/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/b919078cc69fdb46/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/news/632631cd84f1bdbe/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/8ef67f06125e58a1/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/5f2aad2e07121d08/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/125a7060eb16c52b/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/8a291729f9aaf856/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/8094ad421417976d/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/54f6e6b4167455c0/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/e70fd9ea6d476401/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/d8963ea3df7d4bd0/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/ab08d66592c25197/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/d8fd597e8f548569/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/b59c01567c7da6cb/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/b9f0f148cd5daa32/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/ed0db8d4129df83d/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/d496210b132a3f06/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/853051434032f5cb/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/a1dffc06b02b5435/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/677b71b56f67f668/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b4b27483f7005bd/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/2d9236ec2857eec1/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/35f54c3b5ec14784/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e912da4919fee2c/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/169988d27b2a9236/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/4b2aeb356f4eb3d5/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/9eeb407b19386587/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/f28e178e5dd27621/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/ec07f5e8033e28ec/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/ca9f9471fc9f4bb5/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/f5bae38967fb3b37/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/59618e8a0d8b1717/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/65c9324d9ab2edf8/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/d92f183ed45feca3/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/7824bc053789d052/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/bb1e008d15cdd749/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/2b9b44b5cc128aec/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/84ccc2994fb02732/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/e911fa816329abd4/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/6395d10971ee17d3/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/636e86d719472b00/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/d8224fa1853fac63/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/584b2cc4f8b26ec5/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/43e4d7562197b5d8/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/6d1258c4ccb73350/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/2917078f74f169cd/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/980bd6bfeb2a3589/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/ad2f8e01b17c7eba/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/f4d04da3592b503f/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/09ff44d9b1198569/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/9a1984b113ba7bc4/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/523a05f0d908e1a8/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/9a54028973a91cfe/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/92a3fcb84d9d68c1/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/2a2ce08577393632/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/49f09427f9c27010/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/39e78a3ecbd5b6b1/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/773a340502352b71/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/c48c3d92f6de14fa/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/d606c8c5ecd47ae3/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/7a0992e7e562f480/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/0b6cff77f4bb4010/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/9f468fd1d85246b9/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/e284f8a252dc4bcd/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/237b14042d508e8c/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/7946d6d46f084166/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/a6bf139117b22aff/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/3b641dc08b970ea9/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/2101b4a0300eb594/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/news/1c7c4d3265e1ed1c/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/29c46140d443bc6e/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/b5fce276b0a9a303/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/91e3e96fef35c6f3/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/21395953fd7bd2af/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/64bbb64b3f469b3d/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/1bcf03bd66f61cc5/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/e4cf1c57d6516692/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/bd05edc1c9835c25/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/2bba016e6855b43a/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/dc7b2397dd8aef4f/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/8973246e9c86020e/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/7552eb0ac5c905bb/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/d1db1f8944799386/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/c3029a6983f53eb9/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/e78d3c7c3dd22b25/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/f6c9930b5dd7999c/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/afc43d7d0ac9e9e8/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/19684b9883c51d30/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/4605cc4648dc35cd/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/e5e5e0a2fd6272ad/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/87eddc8b855b40a4/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/84a39fff0e294745/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/22f8dfe150415ae7/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/e2d4166a64e1d870/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/ee8c0b5fff92f534/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/dd5533869a6c6d94/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/254984c7664b6e2c/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/9652856c47cd95c4/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/ead552b80c79ee58/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/e7976e729c91d487/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/ebac0d4aca5431c8/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/2f8f94ea612d4efa/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/news/dd759154bb6d2cb4/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/3800f9b633dc20c2/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/ad436771598c05c2/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/d92017e68fb13f00/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/2d62c42ee50c581e/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/news/7650487457ae2b0a/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/news/4e01c6df96b3586f/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/ad9270b3cffc40af/biosergen-completes-enrollment-of-first-cohort-in-bsg005-proof-of-concept-trial 2024-10-07T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/a53270d6d6330266/ge-healthcare-announces-phase-i-results-for-a-first-of-its-kind-macrocyclic-manganese 2024-10-07T06:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/67df6399fc92542c/avillion-announces-positive-high-level-results-from-phase-globenewswire 2024-10-07T06:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/ac24ab39f4858e23/feasibility-of-interdisciplinary-evaluation-in-non-arthritic-hip-pain-a-randomized-trial 2024-10-07T06:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/ee5202d4d0d9f0d8/new-clinical-trial-to-prevent-food-allergies-in-children-opens-king-s-college-london 2024-10-07T06:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/2693f84bd308bdf7/imu-biosciences-joins-ground-breaking-uk-research-globenewswire 2024-10-07T06:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/c95d676849a6bc83/airsupra-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-the-risk 2024-10-07T06:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/d6aae780801e4f9d/addition-to-scientific-advisory-board-company-announcement-investegate 2024-10-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/e3a2cc77882db2ad/formulary-barriers-and-rebate-structures-hinder-adalimumab-biosimilar-adoption-in-us-market 2024-10-07T05:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/d8aa24f15c93d8e3/evaluating-faricimab-in-treatment-naive-neovascular-age-related-macular-degeneration 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/9dccab4d340e7c63/a-novel-procedure-for-treating-radial-keratotomy-rk-induced-corneal-opth 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/a6d7f3f4570f3492/can-cb1-inhibitors-make-a-comeback-in-obesity-biospace 2024-10-07T04:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/2f160f3328539393/viiv-healthcare-triples-hiv-prevention-drug-supply-for-low-income-nations 2024-10-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0107be9a8f7879de/renal-denervation-up-to-date-2024-evidence-and-perspectives-in-japan-nature 2024-10-07T03:55:30+00:00 weekly 0.7 https://trial.medpath.com/news/ad364e62e367c186/concerns-have-been-raised-about-obesity-treatments-which-are-attracting-attention-due-to-the-effect 2024-10-07T02:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/ba48fb4dba5b0539/productlife-group-expands-drug-development-capabilities-with-intiquan-acquisition 2024-10-07T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/20eaf3b675df2944/fda-approves-use-of-up-to-three-tubes-of-biofrontera-inc-s-ameluz-aminolevulinic-acid-hci-topical-gel-10-in-one-treatment 2024-10-07T02:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/75984e0d09588736/preventing-antimicrobial-resistance-not-states-centre-may-approve-new-antibiotics-blue 2024-10-07T01:41:56+00:00 weekly 0.7 https://trial.medpath.com/news/3bb0c6d552e30c71/health-check-long-suffering-mesoblast-investors-dare-to-dream-stockhead 2024-10-07T01:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/7d3180d3fd40e276/rhythm-biosciences-2g-colostat-colorectal-cancer-detection-kit-outperforms-predecessor 2024-10-07T00:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/17d9f0cfc558e0b0/mrna-licensing-deals-surge-to-3-8-billion-as-major-pharma-companies-bet-on-technology-s-future 2024-10-07T00:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/4df2a80638f3dac7/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ab2aba209196b73/leo-pharma-s-temtokibart-shows-comparable-efficacy-to-dupilumab-in-phase-2a-atopic-dermatitis-trial 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e5971e7d9ff3aaeb/heparegenix-raises-eur15-million-series-c-round-to 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/94dda7aa3b5ce66c/simtra-biopharma-solutions-invests-14m-to-expand-adc-manufacturing-capabilities 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2360e0116859fdfb/immuron-welcomes-nmrc-results-for-campylobacter-in-controlled-human-infection-model-study 2024-10-06T23:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/911e0b0c5671bcd3/personalised-radiotherapy-for-people-with-bladder-cancer-shows-promise 2024-10-06T23:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/34b8774a02d3ddac/judo-bio-launches-with-100m-to-pioneer-kidney-targeted-rna-therapeutics 2024-10-06T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/10c5797d974ca795/abivax-enrols-first-participant-in-phase-iib-crohn-s-disease-drug-trial-msn 2024-10-06T21:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/cf45779a0eb69cab/sammy-basso-progeria-advocate-has-died-at-28-stat-news 2024-10-06T21:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/e46c9de087e353b4/strategic-approaches-to-safety-profile-development-in-rare-disease-clinical-trials 2024-10-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/38cb43ff9d28c625/biomarker-testing-crucial-for-personalized-treatment-in-metastatic-nsclc-experts-emphasize 2024-10-06T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/32cdf439a4ed744f/arca-receives-fda-fast-track-designation-for-gencarotm-development-quick-facts 2024-10-06T19:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/652cf0dd86ccf022/rheumatology-month-in-review-september-2024-hcplive 2024-10-06T19:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/3b7b7ee350b5aec6/india-denies-clinical-trial-waivers-for-in-vitro-diagnostics-despite-global-approvals 2024-10-06T19:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/9c6cf69700a6cec4/european-commission-grants-nlx-112-orphan-medicinal-product-designation-neurologylive 2024-10-06T19:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/0204f99a7f437b26/new-drug-to-combat-debilitating-immune-system-disorder-lupus-the-condition-that-left-seal-scarred 2024-10-06T18:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/c38f16ad724c7378/policy-support-important-as-india-largely-an-out-of-pocket-market-panchal 2024-10-06T17:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/66c93d3751682e5e/sun-pharmaceutical-industry-gets-cdsco-panel-nod-to-study-aflibercept-injection 2024-10-06T17:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/04d1ca53a39c631e/aim-vaccine-co-ltd-announces-unblinding-of-data-from-phase-iii-clinical-trial-of-iterative 2024-10-06T16:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/38c47ec248ee71de/glp-1-receptor-agonists-are-a-transformative-prehabilitation-tool-for-weight-loss-in-obese 2024-10-06T15:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/1618ce62dbf65b84/mitsubishi-tanabe-pharma-america-to-present-radicava-ors-r-edaravone-pr-newswire 2024-10-06T14:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/8e216f5f88c5e5f5/science-medicine-studying-the-chemical-miscommunication-that-may-lead-to-obesity 2024-10-06T14:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/3527dd00406d4a7d/human-papillomavirus-hpv-induced-cancers-first-patient-enrolled-in-phase-i-iia-clinical-trial 2024-10-06T14:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/b581b4217aabe184/london-clinical-trial-targets-lingering-covid-toll-on-patients-smell-distortion 2024-10-06T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/f76faa60de64a448/medication-increases-radiation-therapy-s-efficacy-for-lung-cancer-that-has-progressed-to-brain 2024-10-06T13:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/d6710b8d14dd8e51/cedric-pobel-md-phenotypic-and-genomic-analyses-from-peace-1-in-de-novo-mcspc 2024-10-06T13:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/3cecaa9fab306799/immix-and-nexcella-make-progress-in-us-trial-for-light-chain-amyloidosis-car-t-nxc-201 2024-10-06T13:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/8ca5ce0874fff95d/fractional-doses-of-pneumococcal-vaccine-could-bolster-supply-in-under-resourced-regions 2024-10-06T12:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/3cf8a861f8411e5d/otsuka-reports-data-from-phase-iii-alzheimer-s-agitation-trial-msn 2024-10-06T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/a7f8150b7dc1730a/tifr-study-uses-psychedelic-drug-to-trace-neuron-that-can-reduce-anxiety-times-of-india 2024-10-06T09:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/e1601224881f2e59/icmr-to-study-efficacy-of-metformin-inositol-in-pcos-treatment-the-economic-times 2024-10-06T04:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/995971087192a368/meta-correlation-of-the-effect-of-ketamine-and-psilocybin-induced-subjective-effects-on 2024-10-06T03:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/eb5da00df88baa07/tailored-chemotherapy-doses-lead-to-better-outcomes-in-high-risk-breast-cancer 2024-10-06T03:01:25+00:00 weekly 0.7 https://trial.medpath.com/news/d5f76872ad92b9d2/deadly-venom-of-funnel-web-spiders-used-to-develop-breakthrough-drug-for-heart-attack-patients 2024-10-06T02:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/d6b57b00afa6726c/nme8-is-essential-for-protection-against-chemotherapy-drug-cisplatin-induced-male 2024-10-06T01:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/93f78694f72cee5a/new-lung-cancer-drug-offers-hope-as-precision-medicine-advances-shia-waves 2024-10-06T01:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/7f7835ffe74a2eca/clinical-and-immune-responses-to-neoadjuvant-fulvestrant-with-or-without-enzalutamide-in-er-her2 2024-10-06T01:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/4c2d6ca3b4a2bf74/world-first-cancer-treatment-now-accessible-for-hundreds-more-aussies-as-prices-slashed 2024-10-06T01:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/91143de39157985c/eu-the-johnson-and-johnson-vaccine-has-a-possible-link-with-blood-clotting-telegraph 2024-10-06T00:23:05+00:00 weekly 0.7 https://trial.medpath.com/news/9c2453acf07a6c57/research-seeks-to-establish-the-efficacy-of-minimally-invasive-breast-cancer-procedures-and-tests 2024-10-05T22:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/07a745870fef8f91/pelabresib-and-ruxolitinib-show-benefit-in-treating-patients-with-jak-inhibitor-naive-myelofibrosis 2024-10-05T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/fd126bdd1aa4bbe7/lenacapavir-a-breakthrough-in-hiv-prevention-but-challenges-in-access-remai 2024-10-05T21:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/99d00d2db4de384f/exploring-the-use-of-ultra-hypofractionated-rt-in-elderly-breast-cancer 2024-10-05T21:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/459aae856184a30c/relationship-between-sleep-and-pain-the-hippocratic-post 2024-10-05T21:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/93fd3cb695464c61/u-of-virginia-researchers-explore-new-ways-to-manage-diabetes-wtop-news 2024-10-05T20:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/676f7689c7ba9793/a-phase-1-first-in-human-study-evaluating-safety-pharmacokinetics-and-efficacy-of-abbv 2024-10-05T20:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/47d76ec66dfc13d1/top-5-infectious-disease-news-stories-week-of-september-27-october-4-contagion-live 2024-10-05T19:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/e94c25fc56b9b21c/vamorolone-shows-potential-dual-mechanism-as-mineralcorticoid-receptor-antagonist-in 2024-10-05T19:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/a70b0425985765df/suven-life-sciences-to-present-positive-results-from-phase-2a-proof-of-concept-study-of-ropanicant 2024-10-05T17:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/0fafad39ece47939/how-doctors-hope-new-cannabis-drug-will-help-cancer-patients-gain-weight-inews 2024-10-05T17:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/a1ef04e52e7af121/astrazeneca-gets-fda-approval-for-pnh-drug-voydeya-msn 2024-10-05T17:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/913cef871d5ee7ff/horizon-study-update-for-msa-drug-ion464-onaboutlinumtoxina-to-be-tested-in-essential 2024-10-05T17:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/04bcd173b925d182/treatment-persistence-safety-after-switching-to-infliximab-biosimilars-in-canadians-with-ibd 2024-10-05T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/3a1f49fc2aa100ae/this-healthcare-growth-stock-could-be-a-steal-of-a-deal-right-now-the-globe-and-mail 2024-10-05T16:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/f183bd52632596ea/new-gsk-pfizer-moderna-rsv-vaccines-available-for-older-adults-60-fortune-well 2024-10-05T16:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/5076c62cd0da7555/urinary-cyclophilin-a-as-an-early-marker-of-chronic-kidney-disease-with-underlying-type-2-diabetes 2024-10-05T16:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/c40af944b611f1ef/rural-iowa-mothers-face-severe-postpartum-depression-news-kmaland-com 2024-10-05T14:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/4298af201227142b/secukinumab-surpasses-ustekinumab-in-clearing-skin-for-generalized-pustular-psoriasis 2024-10-05T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/303f27b9ba876fe3/new-drug-could-extend-the-lives-of-breast-cancer-patients-news-medical 2024-10-05T14:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/bdfaf886bc2cc634/clinical-trials-of-india-s-first-covid-19-vaccine-to-start-with-375-people-the-commune 2024-10-05T13:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/fb41eb3c1b6939cd/1-ai-biotech-stock-that-just-scored-a-major-milestone-the-globe-and-mail 2024-10-05T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/595b038694bde69b/j-j-discontinues-study-for-investigational-antiviral-for-dengue-prevention-contagion-live 2024-10-05T10:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/337325bc03ba72e6/department-of-defense-funded-research-may-lea-eurekalert 2024-10-05T09:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/697c7a0e2cbfec0f/matching-adjusted-indirect-comparison-of-the-efficacy-and-safety-of-difamilast-1-and 2024-10-05T09:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/ec5eb0a9739f82cc/vaccine-trial-stalls-due-to-fund-crunch-the-daily-star 2024-10-05T08:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/f58ebc5b836afeb7/ge-healthcare-receives-fda-clearance-for-alzheimer-s-imaging-tool-hit-consultant 2024-10-05T08:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/3ef05ad425f069b4/cgtlive-r-s-weekly-rewind-october-4-2024 2024-10-05T07:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/6da10b06397f1853/valbenazine-shows-sustained-treatment-effect-on-huntington-s-chorea-in-kinect-hd2 2024-10-05T07:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/da68fd36d1eee72c/neurologylive-r-friday-5-october-4-2024 2024-10-05T07:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/76cabc372f779568/novel-anti-estrogen-therapies-are-poised-to-expand-treatment-options-in-advanced-er 2024-10-05T06:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/f0e97d9a900d1f2b/inside-information-bioretec-updates-its-product-development-strategy-by-accelerating-the 2024-10-05T06:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/8faa7a49ac675462/groundbreaking-drug-could-make-tooth-loss-a-thing-of-the-past-by-2030-news18 2024-10-05T05:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/e5b137b57b2426b7/ai-pos-and-roi-an-alphabet-soup-of-21st-century-drug-development-life-science-leader 2024-10-05T05:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/278ae20387f8f35f/dear-payers-people-living-with-early-alzheimer-s-disease-are-worth-it-medical-economics 2024-10-05T05:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/5515235f1dbd628c/q-a-roflumilast-cream-0-15-for-ad-with-eric-simpson-md-mcr-faad 2024-10-05T05:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/d99c25d4e9845f6a/i-spy-2-2-is-working-why-aren-t-others-replicating-the-design-biocentury 2024-10-05T05:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/eb14d0683c111781/atezolizumab-plus-platinum-doublet-and-maintenance-niraparib-for-late-relapsing 2024-10-05T04:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/0526081e3a8a5dc1/9-months-of-treatment-with-tralokinumab-results-in-improved-qol-itch-and-sleep 2024-10-05T03:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/e9f007599c8b9780/an-investigator-s-perspective-on-biomarker-guided-antibiotic-treatment-contagion-live 2024-10-05T03:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/b131b1d89215395b/gut-bacteria-engineered-to-act-as-tumor-gps-for-immunotherapies-medical-xpress 2024-10-05T03:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/7486f0632d463f1c/relay-therapeutics-to-lay-off-10-of-workforce-biospace 2024-10-05T03:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/7bde3cb97d62eee7/clinical-trial-relapsed-or-refractory-acute-lymphocytic-leukemia-all-nct06481735 2024-10-05T01:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/2df475b3cd4247f7/kineta-announces-kva12123-abstract-accepted-for-poster-globenewswire 2024-10-05T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/4de5c4cd0835c042/oral-paltusotine-demonstrates-efficacy-in-phase-3-acromegaly-trial-offering-alternative-to-injectable-treatments 2024-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b01a4de7372fe225/breakthrough-blood-test-improves-early-diagnosis-of-pancreatic-cancer-news-medical 2024-10-04T23:41:44+00:00 weekly 0.7 https://trial.medpath.com/news/ab2c0f0a7eadf18c/why-avidity-biosciences-zoomed-to-a-12-gain-this-week-the-globe-and-mail 2024-10-04T23:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/29bea59dcb9e6f00/avidity-biosciences-rna-stock-surges-on-fda-decision-gurufocus 2024-10-04T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/5de932127ef207ec/boy-with-duchenne-s-gets-gene-therapy-3-days-before-he-s-ineligible-exclusive 2024-10-04T22:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/61db14bb4d31fe7c/novel-radioconjugate-or-conventional-care-prior-to-allogeneic-hematopoietic-cell 2024-10-04T22:37:33+00:00 weekly 0.7 https://trial.medpath.com/news/6254b3ab6c74e54c/tranexamic-acid-during-radical-cystectomy-a-randomized-clinical-trial-urotoday 2024-10-04T22:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/042316b5e6b6cc5e/nivolumab-rt-improves-biochemical-recurrence-outcomes-in-prostate-cancer 2024-10-04T21:53:08+00:00 weekly 0.7 https://trial.medpath.com/news/6b59bacda5add4a2/island-pharmaceuticals-trials-prevention-and-therapy-benefit-of-dengue-drug 2024-10-04T21:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/bff4cfedbfa2fcf2/dr-machaalani-on-the-incidence-of-erbb2-amplifications-across-race-sex-and-cancer-type 2024-10-04T21:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/fdd753bf5a7ffa87/cms-initiates-coverage-review-for-abbott-triclip-system-massdevice 2024-10-04T18:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/8b9b374f2956ad7b/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-antibody 2024-10-04T18:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/621267e771b6759e/ema-reviews-hair-loss-products-following-concerns-about-suicidal-thoughts 2024-10-04T18:28:07+00:00 weekly 0.7 https://trial.medpath.com/news/14cfc4acd850ebdc/plasma-egfr-mutation-ctdna-dynamics-in-patients-with-advanced-egfr-mutated-nsclc 2024-10-04T17:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/ea6e4ee67e5b7c58/onco360-r-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra 2024-10-04T17:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/2134b81c38a1f577/opdivo-gets-perioperative-approval-pharmas-cut-jobs-in-new-jersey-ireland 2024-10-04T17:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/578132742ddff971/oncolytics-biotech-r-announces-key-progress-and-upcoming-studies-for-breast-pr-newswire 2024-10-04T17:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/0170f6f9c1198ba1/global-mrna-cancer-vaccine-clinical-trial-fda-approval-globenewswire 2024-10-04T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/6ef28b5fc783c596/studying-a-culturally-tailored-anti-inflammatory-diet-s-impact-on-hispanic-latinx-patients 2024-10-04T16:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/efeca1230080877a/alpha-cognition-announces-executive-shake-up-drug-approval-tipranks-com 2024-10-04T16:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/11680b33204f0475/an-alzheimer-s-drugmaker-is-accused-of-data-manipulation-should-its-trials-be-stopped 2024-10-04T16:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/f1ddf80fb952d572/affimed-n-v-advances-in-clinical-development-of-novel-therapies-for-solid-and-liquid-tumors 2024-10-04T16:35:04+00:00 weekly 0.7 https://trial.medpath.com/news/928d0974579a0349/magic-g1-study-provides-updated-findings-with-mtx110-in-recurrent-glioblastoma 2024-10-04T16:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/a6e5142ce72018f0/pen-bay-waldo-expand-cardiac-rehab-offerings-mainehealth 2024-10-04T16:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/8dbcb066efbc30e9/highlights-in-non-prostate-gu-oncology-from-esmo-2024-ignacio-duran-urotoday 2024-10-04T16:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/49c58339522c26b8/alembic-receives-usfda-final-approval-for-alcaftadine-ophthalmic-solution-0-25-otc 2024-10-04T15:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/1a0a2e12b5c2adf7/chronic-urticaria-competitive-landscape-assessment-2024-globenewswire 2024-10-04T15:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/e353c75652fc0358/variation-in-opioid-agonist-dosing-in-clinical-trials-by-race-and-ethnicity-jama-network 2024-10-04T15:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/689ad3d049f3d06b/lanzatech-to-produce-30000-tonnes-of-microbial-protein-per-annum-the-fish-site 2024-10-04T15:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/3a3427b98828fbcc/vividion-continues-to-teach-covalent-compounds-new-tricks 2024-10-04T15:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/1b15f5e0dbaf3b73/case-report-allogeneic-culture-expanded-bone-marrow-derived-mesenchymal-stem-cells-for 2024-10-04T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/a0806073be581150/myeloproliferative-neoplasms-treatment-new-insights-hematology-advisor 2024-10-04T15:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/0366585a0eb0984b/tiumbio-announces-first-patient-dosed-in-phase-2-clinical-trial-of-oral-immuno-oncology 2024-10-04T15:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/c595ecaebff587ea/amazing-trial-shows-drug-combination-stops-lung-cancer-advancing-for-longer 2024-10-04T14:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/cd9497561a3e49fa/wuxi-companies-consider-asset-sales-amid-us-biosecure-act-pressure 2024-10-04T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/058c4fa878000493/summit-therapeutics-stock-jumps-as-lung-cancer-drug-placed-on-fda-fast-track 2024-10-04T14:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/83a2a07d03950a35/fda-approves-16-new-cancer-treatments-as-global-cancer-rates-skyrocket-kilgore-news-herald 2024-10-04T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/e052609b0683db05/indoco-remedies-receives-u-s-fda-approval-for-generic-cetirizine-tablets 2024-10-04T13:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/d74bc67e3568f326/a-compound-analysis-of-medical-device-clinical-trials-registered-in-africa-on-clinicaltrials-gov 2024-10-04T13:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/49d862094ad28e40/emavusertib-focused-research-is-poised-to-expand-the-pcnsl-treatment-paradigm 2024-10-04T13:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/f239611b319afc60/turkey-brazil-emerging-as-clinical-trial-destinations-for-cancer-drugs-biospace 2024-10-04T13:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/36c9105fa7e920de/h-c-wainwright-keeps-buy-rating-on-summit-therapeutics-stock-highlighting-fast-track-designation 2024-10-04T13:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/e6d61af1112c11a7/cytodyn-engages-syneos-health-as-cro-for-its-phase-ii-oncology-trial 2024-10-04T12:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/cf424492c93a1c16/the-first-six-months-of-the-2024-voluntary-scheme 2024-10-04T12:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/535add5ad1c24d86/trevi-therapeutics-provides-update-on-haduvio-s-clinical-development-program 2024-10-04T12:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/808aff7db8d97c3d/biodexa-provides-update-on-progression-free-and-overall-globenewswire 2024-10-04T12:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd87c7bf4c05c27f/sapience-therapeutics-announces-participation-at-the-4th-annual-needham-private-biotech 2024-10-04T12:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/056f74ef0ed07109/treatment-selection-landscape-evolves-for-egfr-nsclc-with-new-therapeutic-options 2024-10-04T12:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/a1bee1eae8a08afc/avistone-announces-updates-on-ans014004-yahoo-finance 2024-10-04T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/37dbcb5a266cd249/creation-of-de-novo-cryptic-splicing-for-als-and-ftd-precision-medicine-pubmed 2024-10-04T11:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/8eff5960acc6b7d8/oxcia-is-focusing-the-development-of-oxc-101-on-hematological-cancers-cision-news 2024-10-04T11:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/742ed2a0e464b801/hepatocellular-carcinoma-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-10-04T11:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/231e9ce0812544db/pompe-disease-clinical-trials-2024-updates-ema-pdma-fda-openpr-com 2024-10-04T11:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/438743bc866c25cf/turkish-nobel-scientist-aziz-sancar-s-brain-cancer-breakthrough-enters-human-trials 2024-10-04T11:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/9ec8cd01e6f38b85/anti-cd70-antibodies-clinical-trials-fda-approval-cd70-globenewswire 2024-10-04T11:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/1ad18f91f278125d/global-lag-3-antibody-fda-approval-clinical-trials-lag-3-globenewswire 2024-10-04T11:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/e8faa332fa8ec13e/airdrie-family-seeks-support-for-potential-life-saving-drug-trial-in-the-u-s 2024-10-04T11:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/6326f82a59ea0e17/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-quantisnow 2024-10-04T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/b67a51d4da51720d/fda-approves-exact-sciences-cologuard-plus-test-setting-a-new-benchmark-in-non 2024-10-04T10:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/bb9f6a1c6d7e91b2/mpox-vaccine-s-protection-wanes-within-1-year-boosters-needed 2024-10-04T09:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/0bc82e45b90fc70f/abl-bio-announces-clinical-collaboration-to-evaluate-abl103-in-combination-with-biospace 2024-10-04T08:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/c2b4695090a7e815/mckesson-launches-inspirogene-to-revolutionize-cell-and-gene-therapy-commercialization 2024-10-04T06:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/b4c39bd88c51d844/fda-grants-dual-approval-for-amivantamab-in-non-small-cell-lung-cancer-treatment 2024-10-04T05:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/cb53ec2ac9437711/aldeyra-therapeutics-resubmits-new-drug-application-for-reproxalap-for-the-treatment-of-dry 2024-10-04T05:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/e4d916765cb185ae/breast-cancer-treatment-advances-drive-90-survival-rate-in-early-stage-disease-expert-highlights-progress 2024-10-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f727411900f29f8c/alzheimer-s-mab-policies-do-not-set-precedent-for-accelerated-approval-cms-s-former-cmo-says 2024-10-04T04:24:38+00:00 weekly 0.7 https://trial.medpath.com/news/1b6c7b8be5c4d1e9/fda-approves-presurgical-postsurgical-opdivo-for-nsclc-cure-today 2024-10-04T03:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/62926f31862a2083/ultragenyx-provides-update-on-stage-1-cohorts-in-pivotal-phase-1-2-3-cyprus2-study 2024-10-04T03:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/d9a9c20686a2be4c/international-experts-to-gather-for-als-symposium-in-chicago-news-medical 2024-10-04T02:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/a9a0fd69efdfbe5f/recordati-acquires-global-rights-to-sanofi-s-cad-treatment-enjaymo-in-825m-deal 2024-10-04T02:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/411e52ceec101389/cell-therapy-weekly-promising-phase-i-results-for-parkinson-s-disease-cell-therapy-regmednet 2024-10-04T01:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/b0019653c5dc8c74/first-patient-dosed-achieves-complete-response-in-estrella-immunopharma-s-trial-for-cgtlive-r 2024-10-04T01:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/e6a71b1fb24ae858/neoadjuvant-toripalimab-plus-axitinib-for-clear-cell-renal-cell-carcinoma-with-inferior-vena 2024-10-04T01:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/4d65df2884ba5b3f/anvs-annovis-bio-inc-latest-stock-news-market-updates 2024-10-04T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/831f0c52139632fd/abivax-announces-first-patient-enrolled-in-enhance-cd-the-phase-2b-trial-of-biospace 2024-10-04T00:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/f1f8e95c6b520805/allegheny-general-hospital-among-nation-s-top-enrollment-sites-for-clinical-trial-exploring 2024-10-04T00:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/21761d164391de1a/world-first-ovarian-cancer-vaccine-being-developed-in-uk-the-independent 2024-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0659fd5f334bdadf/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-globenewswire 2024-10-03T23:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/f86a1f58e3ef247b/gastroenterology-month-in-review-september-2024-hcplive 2024-10-03T23:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/7539bbab8392f472/cellprothera-begins-long-term-observational-study-to-demonstrate-safety-and-efficacy-of 2024-10-03T22:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/e2567462114bf91d/fda-approves-uva-health-tested-lung-cancer-treatment-wvir 2024-10-03T22:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/3edb7f86e575dc6d/steap1-targeted-t-cell-engager-demonstrates-efficacy-in-mcrpc-patients-william-kevin-kelly 2024-10-03T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/07425101b9917490/cancer-program-receives-platinum-award-for-patient-participation-in-cancer-research 2024-10-03T21:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/c56040f5ae58d2a9/investigation-of-serum-neurofilament-light-chain-as-a-biomarker-in-fabry-disease-nature 2024-10-03T20:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/96fea108329a669a/nsf-nih-and-fda-support-research-in-digital-twin-technology-for-biomedical-applications 2024-10-03T20:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/a4ccee93e0205cbe/dr-girard-on-pros-from-the-luminosity-trial-in-c-met-overexpressing-nsclc-onclive 2024-10-03T19:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/64b9557b7271a42e/ge-healthcare-s-mim-software-wins-fda-clearance-for-monte-carlo-dosimetry-massdevice 2024-10-03T19:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/339e2e149ad43ecc/future-of-oral-small-molecule-drugs-addressing-potential-in-multiple-sclerosis 2024-10-03T19:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/a760cf5f64747eb7/grand-rounds-september-27-2024-azithromycin-for-childhood-mortality-rethinking-clinical-trials 2024-10-03T18:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/ba138c34a49ab3df/phase-iii-trial-fedratinib-reduces-spleen-size-in-ruxolitinib-refractory-myelofibrosis 2024-10-03T18:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/7e25737c9eb23502/nhs-england-proposes-phased-launch-of-obesity-injection-pf-media 2024-10-03T18:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/bb964a66e4b4b8cf/stemcyte-s-hpc-cord-blood-receives-rmat-designation-for-long-covid-19-treatment 2024-10-03T18:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/e70d529d9f03554f/artax-biopharma-to-present-first-in-class-nck-modulator-mechanism-of-action-and-phase-1 2024-10-03T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/b6f072b2ad9730a2/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxion-s-ai 2024-10-03T18:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/bc7f3e173bfda749/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma 2024-10-03T18:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/e00a07d174078967/ec-approves-daiichi-sankyo-s-vanflyta-for-acute-myeloid-leukaemia-msn 2024-10-03T17:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/1518d0273f65d3e5/fda-grants-breakthrough-device-designation-to-amphix-bio-s-bone-regeneration-product 2024-10-03T17:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/6144d24c574e0481/therivatm-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee 2024-10-03T17:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/49058098de6d5257/long-term-trial-data-boosts-case-for-newer-drug-resistant-tb-regimens-cidrap 2024-10-03T17:19:28+00:00 weekly 0.7 https://trial.medpath.com/news/ca074fb974c45a60/ketamine-pills-could-finally-offer-depression-breakthrough-miriam-stoppard-mirror-online 2024-10-03T17:14:21+00:00 weekly 0.7 https://trial.medpath.com/news/32268ca0d118fc0d/parkinson-s-therapy-nd0612-reduces-off-time-increases-on-time-after-a-year 2024-10-03T17:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/a5faa383e8daf0c8/virtual-family-centered-rounds-help-parents-support-their-child-s-care-uc-davis-health 2024-10-03T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/f7e2863d01108d27/alfasigma-receives-green-light-to-sell-jyseleca-in-europe-born2invest 2024-10-03T16:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/135def5e9b99eda1/nucleos-t-ide-analogs-to-treat-patients-with-positive-hepatitis-b-virus-deoxyribonucleic-acid 2024-10-03T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/f8deac2bd5018d95/after-40m-settlement-alzheimer-s-drug-under-scrutiny-as-human-trials-proceed 2024-10-03T16:21:22+00:00 weekly 0.7 https://trial.medpath.com/news/e08aa1fa1c2daaa1/assessment-of-antitachycardia-pacing-in-primary-prevention-patients-jama-network 2024-10-03T16:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/548492357141211b/emerging-dll3-targeted-therapies-demonstrate-efficacy-in-neuroendocrine-prostate-cancer 2024-10-03T16:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/bd6436dc3e2fedfc/veracyte-s-rna-genetic-test-predicts-black-men-s-aggressive-prostate-cancer 2024-10-03T16:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/0b0af09fdf1d630a/six-biotechs-driving-progress-in-duchenne-muscular-dystrophy-labiotech-eu 2024-10-03T15:59:11+00:00 weekly 0.7 https://trial.medpath.com/news/b5a3f3f324d6c7e3/can-eye-drops-replace-surgery-for-curing-cataracts-theu 2024-10-03T15:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/fc5499d58c3886fa/adjuvant-nivolumab-vs-placebo-in-localized-renal-cell-carcinoma-at-high-risk-of 2024-10-03T15:53:29+00:00 weekly 0.7 https://trial.medpath.com/news/d0d1829b3c949337/autologous-vs-allogeneic-stem-cell-transplantation-in-younger-patients-with-peripheral-t 2024-10-03T15:50:31+00:00 weekly 0.7